[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 92 of about 92
1. Assimakopoulou M, Kondyli M, Gatzounis G, Maraziotis T, Varakis J: Neurotrophin receptors expression and JNK pathway activation in human astrocytomas. BMC Cancer; 2007;7:202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurotrophin receptors expression and JNK pathway activation in human astrocytomas.
  • The aim of this exploratory study was to investigate the expression levels of neurotrophin receptors, Trks and p75NTR, and the activation of JNK pathway in human astrocytomas and in adjacent non-neoplastic brain tissue.
  • METHODS: Formalin-fixed paraffin-embedded serial sections from 33 supratentorial astrocytomas (5 diffuse fibrillary astrocytomas, WHO grade II; 6 anaplastic astrocytomas, WHO grade III; 22 glioblastomas multiforme, WHO grade IV) were immunostained following microwave pretreatment.
  • CONCLUSION: In the context of astrocytomas, Trk receptors (TrkA, TrkB, TrkC) expression may promote tumor growth independently of grade.
  • Considering the fact that regional tumor heterogeneity may be a limiting factor for immunohistochemical studies, the significance of the reverse relationship between Trk receptors and pc-Jun/pJNK LIs with respect to biological behavior of human astrocytomas requires further evaluation.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. MAP Kinase Kinase 4 / metabolism. Nerve Tissue Proteins / biosynthesis. Nerve Tissue Proteins / genetics. Receptors, Nerve Growth Factor / biosynthesis. Receptors, Nerve Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1027-35 [10694553.001]
  • [Cites] Mol Cell Neurosci. 2007 Feb;34(2):271-9 [17188890.001]
  • [Cites] Curr Opin Neurobiol. 2000 Jun;10(3):381-91 [10851172.001]
  • [Cites] Cell. 2000 Oct 13;103(2):239-52 [11057897.001]
  • [Cites] Curr Opin Neurobiol. 2001 Jun;11(3):272-80 [11399424.001]
  • [Cites] Cancer Lett. 2001 Aug 28;169(2):107-14 [11431098.001]
  • [Cites] Curr Opin Pharmacol. 2001 Aug;1(4):398-403 [11710739.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):250-5 [12517805.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):203-16 [12612655.001]
  • [Cites] J Biosci. 2003 Mar;28(2):181-8 [12711810.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14421-6 [14614136.001]
  • [Cites] Nat Rev Neurosci. 2003 Apr;4(4):299-309 [12671646.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):133-42 [14638850.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):430-46 [15136790.001]
  • [Cites] Childs Nerv Syst. 2004 Jun;20(6):412-9 [15138791.001]
  • [Cites] Brain Res. 2004 Aug 13;1017(1-2):53-60 [15261099.001]
  • [Cites] Neurochem Int. 1997 Apr-May;30(4-5):347-74 [9106250.001]
  • [Cites] J Neurosci. 1997 Jan 15;17(2):530-42 [8987776.001]
  • [Cites] Acta Neuropathol. 1998 Apr;95(4):325-32 [9560008.001]
  • [Cites] Acta Neuropathol. 1998 Oct;96(4):357-64 [9797000.001]
  • [Cites] Eur J Neurosci. 2005 Jan;21(2):363-77 [15673436.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):137-60 [15674475.001]
  • [Cites] J Neurosci. 2005 Jun 1;25(22):5455-63 [15930396.001]
  • [Cites] Anat Sci Int. 2005 Dec;80(4):223-8 [16333918.001]
  • [Cites] Curr Alzheimer Res. 2006 Feb;3(1):19-24 [16472198.001]
  • [Cites] J Neurosci. 2006 Jul 19;26(29):7756-66 [16855103.001]
  • [Cites] J Neurooncol. 1999;45(1):1-8 [10728904.001]
  • (PMID = 17971243.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NGFR protein, human; 0 / Nerve Tissue Proteins; 0 / Receptors, Nerve Growth Factor; 0 / bcl-2-Associated X Protein; EC 2.7.10.1 / Receptor, trkA; EC 2.7.10.1 / Receptor, trkB; EC 2.7.10.1 / Receptor, trkC; EC 2.7.12.2 / MAP Kinase Kinase 4
  • [Other-IDs] NLM/ PMC2180182
  •  go-up   go-down


2. Sievert AJ, Jackson EM, Gai X, Hakonarson H, Judkins AR, Resnick AC, Sutton LN, Storm PB, Shaikh TH, Biegel JA: Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol; 2009 Jul;19(3):449-58
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene.
  • In the present study, DNA from 28 pediatric low-grade astrocytomas was analyzed using Illumina HumanHap550K single-nucleotide polymorphism oligonucleotide arrays.
  • A novel duplication in chromosome band 7q34 was identified in 17 of 22 juvenile pilocytic astrocytomas and three of six fibrillary astrocytomas.
  • Further studies are required to determine the role of this fusion gene in downstream MAPK signaling and its role in development of pediatric low-grade astrocytomas.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2003 Sep;53(3):544-53; discussion 554-5 [12943571.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):197-207 [12816726.001]
  • [Cites] Cancer Res. 1988 Jan 1;48(1):175-80 [3334992.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Apr;86(8):2858-62 [2565039.001]
  • [Cites] Nature. 1992 Feb 27;355(6363):846-7 [1311419.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Mar;59(1):12-9 [1313329.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Nov;71(1):40-9 [8275451.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1324-30 [8118823.001]
  • [Cites] Hum Pathol. 1995 Sep;26(9):979-86 [7672798.001]
  • [Cites] Med Pediatr Oncol. 1995 Dec;25(6):431-6 [7565304.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Apr;15(4):199-205 [8703845.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2792-9 [9256121.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Sep;97(2):125-34 [9283596.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):94-101 [15630448.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):207-10 [15791479.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7152-60 [16192599.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):396-402 [16353203.001]
  • [Cites] Genome Res. 2006 Sep;16(9):1136-48 [16899659.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):347-51 [17293865.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):121-33 [17588166.001]
  • [Cites] Hum Genet. 2007 Sep;122(2):117-27 [17541642.001]
  • [Cites] J Mol Diagn. 2007 Sep;9(4):464-71 [17690212.001]
  • [Cites] Hum Mol Genet. 2007 Oct 15;16(20):2506-16 [17656373.001]
  • [Cites] Oncogene. 2008 Feb 7;27(7):877-95 [17724477.001]
  • [Cites] Pediatr Dev Pathol. 2008 Mar-Apr;11(2):108-17 [17990938.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4745-51 [18408760.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):693-702 [17290307.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):779-86 [11549567.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):503-11 [11585322.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):153-60 [12816721.001]
  • [ErratumIn] Brain Pathol. 2009 Jul;19(3):550
  • (PMID = 19016743.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA133173-01; United States / NIGMS NIH HHS / GM / GM081519; United States / NCI NIH HHS / CA / CA133173; United States / NCI NIH HHS / CA / R21 CA133173; United States / NCI NIH HHS / CA / CA133173-01; United States / NIGMS NIH HHS / GM / R01 GM081519
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Other-IDs] NLM/ NIHMS184143; NLM/ PMC2850204
  •  go-up   go-down


3. Liu J, Lu H, Ohgaki H, Merlo A, Shen Z: Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas. BMC Cancer; 2009 Aug 04;9:268
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas.
  • BACKGROUND: Loss of heterozygosity of chromosome 10q26 has been shown to be associated with the aggressiveness of astrocytic tumors (or astrocytomas), but the responsible gene(s) residing in this region has not been fully identified.
  • In this study, we investigated whether BCCIP is altered in astrocytomas.
  • IHC staining of glial fibrillary acid protein (GFAP), a marker for astrocytic cells, was used to identify cells of the astrocytic lineage.
  • CONCLUSION: Our data implicate a role of BCCIP in astrocytic tumorigenesis, and lack of BCCIP may be used as a marker for astrocytomas.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol Res. 1999 Oct;291(10):567-9 [10552217.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Jul;5(1):75-82 [1384665.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1371-7 [10604735.001]
  • [Cites] Lab Invest. 2000 Jan;80(1):65-72 [10653004.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31145-54 [10878006.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):620-5 [11058880.001]
  • [Cites] Acta Neuropathol. 2001 Mar;101(3):185-9 [11307615.001]
  • [Cites] Hum Genet. 1993 Sep;92(2):169-74 [8370584.001]
  • [Cites] Brain Pathol. 1994 Jul;4(3):229-37 [7952264.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1922-6 [7728760.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):2143-7 [8616863.001]
  • [Cites] Oncogene. 1997 Aug 18;15(8):997-1000 [9285695.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):32-9 [9288095.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4905-12 [9354456.001]
  • [Cites] Br J Cancer. 1998;77(2):270-6 [9460998.001]
  • [Cites] Oncol Rep. 1998 Jan-Feb;5(1):213-6 [9458379.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Aug;22(4):295-304 [9669667.001]
  • [Cites] Oncogene. 1998 Jun 25;16(25):3331-5 [9681833.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1329-35 [9769364.001]
  • [Cites] Oncogene. 1998 Oct 1;17(13):1749-53 [9796705.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Feb;24(2):135-43 [9885980.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):387-94 [10433932.001]
  • [Cites] J Mol Med (Berl). 2004 Oct;82(10):656-70 [15316624.001]
  • [Cites] Cell Cycle. 2004 Nov;3(11):1457-62 [15539944.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):125-36 [15674474.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(5):1949-57 [15713648.001]
  • [Cites] Neuropathology. 2005 Mar;25(1):1-7 [15822813.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1571-83 [16247447.001]
  • [Cites] Cell. 2006 Apr 21;125(2):229-31 [16630811.001]
  • [Cites] Am J Hum Genet. 2006 Jun;78(6):1066-74 [16685657.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):184-96 [16412571.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] Cell Cycle. 2006 Oct;5(20):2381-9 [17102621.001]
  • [Cites] J Biol Chem. 2007 Jan 19;282(3):1570-6 [17135243.001]
  • [Cites] Oncogene. 2007 Sep 20;26(43):6253-60 [17452982.001]
  • [Cites] Nucleic Acids Res. 2007;35(21):7160-70 [17947333.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2699-707 [18413737.001]
  • [Cites] Radiother Oncol. 2009 Feb;90(2):183-8 [19046788.001]
  • [Cites] Oncogene. 2001 Jan 18;20(3):336-45 [11313963.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1790-6 [11912156.001]
  • [Cites] J Neurosurg. 2002 Dec;97(6):1397-401 [12507139.001]
  • [Cites] Gene. 2003 Jan 2;302(1-2):139-46 [12527204.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):76-81 [12672033.001]
  • [Cites] Adv Anat Pathol. 2003 Jul;10(4):212-7 [12826827.001]
  • [Cites] Neurosurg Rev. 2003 Jul;26(3):145-58 [12783270.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):992-5 [14559981.001]
  • [Cites] Science. 2003 Oct 24;302(5645):591-3 [14576418.001]
  • [Cites] Biochem J. 2004 Aug 15;382(Pt 1):1-11 [15193142.001]
  • [Cites] Dev Biol. 2004 Sep 15;273(2):175-84 [15328005.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):789-95 [15375501.001]
  • [Cites] Cell Cycle. 2004 Mar;3(3):343-8 [14726710.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Cell. 1999 Oct 29;99(3):323-34 [10555148.001]
  • (PMID = 19653894.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115488
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCCIP protein, human; 0 / BRCA2 Protein; 0 / Calcium-Binding Proteins; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins
  • [Other-IDs] NLM/ PMC2736977
  •  go-up   go-down


Advertisement
4. Shannon P, Sabha N, Lau N, Kamnasaran D, Gutmann DH, Guha A: Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model. Am J Pathol; 2005 Sep;167(3):859-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model.
  • We previously characterized a genetically engineered mouse astrocytoma model with embryonic astrocyte-specific, activated (12)V-Ha-RAS (GFAP-RAS) transgenesis.
  • The GFAP-RAS line Ras-B8 appears normal at birth, but 50% of mice die by 4 months from low- and high-grade astrocytomas.
  • We examined the development and progression of astrocytomas in the Ras-B8 genetically engineered mouse.
  • From 3 to 8 weeks the incidence of low-grade astrocytomas progressively increased with 85% of 12-week-old mice harboring low- or high-grade astrocytomas, the latter characterized by increased proliferation, nuclear atypia, and angiogenesis.
  • Tp 53 mutations were detected in both astrocytoma grades, with high-grade astrocytomas expressing elevated levels of epidermal growth factor receptor and vascular endothelial growth factor, plus decreased levels of PTEN and p16, similar to human astrocytomas.
  • Of interest, many of these acquired alterations occur in human astrocytomas, further validating GFAP-RAS as a useful model for studying astrocytoma development and progression.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 May 1;61(9):3826-36 [11325859.001]
  • [Cites] Exp Neurol. 1999 Jun;157(2):327-37 [10364444.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):289-96 [11718261.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Oncogene. 2002 Oct 24;21(49):7453-63 [12386807.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):335-42 [12584185.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1106-13 [12615729.001]
  • [Cites] Acta Neuropathol. 1978 Jan 19;41(1):27-31 [636834.001]
  • [Cites] Acta Neuropathol. 1979 Mar 15;45(3):167-75 [442982.001]
  • [Cites] Oncogene. 1999 Dec 9;18(52):7514-26 [10602510.001]
  • [Cites] Oncogene. 2000 Aug 10;19(34):3948-54 [10951588.001]
  • [Cites] Brain Res. 2000 Nov 10;883(1):87-97 [11063991.001]
  • [Cites] Neuro Oncol. 2001 Jan;3(1):1-10 [11305411.001]
  • [Cites] J Cell Biol. 1980 Jun;85(3):890-902 [6248568.001]
  • [Cites] Cancer Res. 1986 Nov;46(11):5836-41 [3756925.001]
  • [Cites] Cancer Res. 1991 Nov 15;51(22):6202-5 [1933879.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1974-80 [1551126.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5334-41 [1382841.001]
  • [Cites] Cancer Res. 1993 Jun 1;53(11):2614-7 [8495424.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Oct;77(4):1054-8 [8408453.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):5124-8 [8197195.001]
  • [Cites] Gynecol Oncol. 1995 Dec;59(3):423-6 [8522268.001]
  • [Cites] Br J Cancer. 1996 Jul;74(2):165-71 [8688317.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5141-5 [8912848.001]
  • [Cites] Neurosurgery. 1997 May;40(5):1016-26 [9149260.001]
  • [Cites] Oncogene. 1997 Dec 4;15(23):2755-65 [9419966.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):118-24 [10077162.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4425-31 [11389071.001]
  • (PMID = 16127163.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS041097; United States / NINDS NIH HHS / NS / NS41097
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Growth Substances; 0 / Nerve Tissue Proteins; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC1698742
  •  go-up   go-down


5. Tran Thang NN, Derouazi M, Philippin G, Arcidiaco S, Di Berardino-Besson W, Masson F, Hoepner S, Riccadonna C, Burkhardt K, Guha A, Dietrich PY, Walker PR: Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development. Cancer Res; 2010 Jun 15;70(12):4829-39
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development.
  • To address these issues, we analyzed a transgenic mouse model of spontaneous astrocytoma (GFAP-V(12)HA-ras mice), which allows the study of immune interactions with developing glioma, even at early asymptomatic stages.
  • Overall, our results show an early defective endogenous immune response to gliomas, and local accumulation of immunosuppressive cells at the tumor site.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Lymphocytes, Tumor-Infiltrating / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Animals. CD8-Positive T-Lymphocytes / immunology. Cell Movement. Flow Cytometry. Glial Fibrillary Acidic Protein / metabolism. Granzymes / metabolism. Humans. Immunoenzyme Techniques. Immunosuppression. Lymphocyte Activation. Mice. Mice, Transgenic. Proto-Oncogene Proteins p21(ras) / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501837.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Worldwide Cancer Research / / 05-0465
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; EC 3.4.21.- / Granzymes; EC 3.4.21.- / Gzmb protein, mouse; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


6. Bayrakli F, Dinçer A, Sav A, Vardareli E, Peker S: Late brain stem radionecrosis seventeen years after fractionated radiotherapy. Turk Neurosurg; 2009 Apr;19(2):182-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a 24-year-old patient who suffered from right-sided hemiparesis and ataxic gait with a history of an operation due to left frontoparieal grade II fibrillary astrocytoma and fractioned radiotherapy.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Brain Stem / pathology. Radiation Injuries / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19431132.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


7. Gururangan S, Fisher MJ, Allen JC, Herndon JE 2nd, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, Phillips PC, Watral MA, Krauser JM, Friedman AH, Friedman HS: Temozolomide in children with progressive low-grade glioma. Neuro Oncol; 2007 Apr;9(2):161-8
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Best responses in the 26 patients (86%) with optic pathway glioma (OPG)/pilocytic astrocytoma (PA) included partial response in 3 patients (11%), minor response in 1 (4%), stable disease in 10 (38%), and progressive disease in 12 (46%).
  • Only one of four patients with fibrillary astrocytoma had stable disease for 29 months after TMZ.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Nov;81(6):1022-30 [10576660.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):79-82 [16443951.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):152-62 [11285553.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2388-99 [11981013.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2951-8 [12089224.001]
  • [Cites] Mol Cancer Ther. 2002 Sep;1(11):943-8 [12481416.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1004-11 [12671695.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 May;25(5):372-8 [12759623.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1715-21 [14630674.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1722-6 [14630675.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3728-36 [15173079.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Neurol Clin. 1991 May;9(2):479-95 [1944111.001]
  • [Cites] J Neurooncol. 1997 May;32(3):235-41 [9049885.001]
  • [Cites] J Neurosurg. 1997 May;86(5):747-54 [9126887.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3037-43 [9738573.001]
  • [Cites] Ann Neurol. 1999 Mar;45(3):393-6 [10072056.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2747-55 [15814657.001]
  • [Cites] Ann Hematol. 2005 Oct;84(11):760-2 [16044311.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7646-53 [16234526.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):301-7 [16195800.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2585-97 [10914698.001]
  • (PMID = 17347491.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ PMC1871667
  •  go-up   go-down


8. Henderson MA, Fakiris AJ, Timmerman RD, Worth RM, Lo SS, Witt TC: Gamma knife stereotactic radiosurgery for low-grade astrocytomas. Stereotact Funct Neurosurg; 2009;87(3):161-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife stereotactic radiosurgery for low-grade astrocytomas.
  • Patients with low-grade astrocytoma (LGA; 8 pilocytic astrocytomas, 2 subependymal giant cell astrocytomas, 2 fibrillary astrocytomas) were selected for treatment with gamma knife stereotactic radiosurgery (GKSRS) based on having a demarcated appearance on CT or MRI and the possibility of dose sparing of adjacent eloquent structures.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Radiosurgery / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel.
  • (PMID = 19321969.001).
  • [ISSN] 1423-0372
  • [Journal-full-title] Stereotactic and functional neurosurgery
  • [ISO-abbreviation] Stereotact Funct Neurosurg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


9. Odreman F, Vindigni M, Gonzales ML, Niccolini B, Candiano G, Zanotti B, Skrap M, Pizzolitto S, Stanta G, Vindigni A: Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res; 2005 May-Jun;4(3):698-708
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic studies on low- and high-grade human brain astrocytomas.
  • Human brain astrocytomas range from the indolent low-grade to the highly infiltrating and aggressive high-grade form, also known as glioblastoma multiforme.
  • In this study, we compared the protein pattern of low-grade fibrillary astrocytomas to that of glioblastoma multiforme by 2D electrophoresis.
  • Among the proteins more highly expressed in glioblastoma multiforme, we found peroxiredoxin 1 and 6, the transcription factor BTF3, and alpha-B-crystallin, whereas protein disulfide isomerase A3, the catalytic subunit of the cAMP-dependent protein kinase, and the glial fibrillary acidic protein are increased in low-grade astrocytomas.
  • Our findings contribute to deepening our knowledge of the factors that characterize this class of tumors and, at the same time, can be applied toward the development of novel molecular biomakers potentially useful for an accurate classification of the grade of astrocytomas.
  • [MeSH-major] Astrocytoma / chemistry. Neoplasm Proteins / analysis. Proteomics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15952716.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


10. Frenay MP, Fontaine D, Vandenbos F, Lebrun C: First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas. Eur J Neurol; 2005 Sep;12(9):685-90
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas.
  • At the present time, there are no proven beneficial effects of chemotherapy (CT) for the treatment of pure low-grade astrocytomas.
  • Brain radiotherapy (RT) still remains the standard treatment in order to reduce or delay tumor progression or symptoms, despite possible long-term neurologic complications.
  • We report 10 patients, with histologically proven pure low-grade fibrillary astrocytomas, to which we administered a first-line nitrosourea-based CT.
  • These results demonstrate that some patients with symptomatic non-resectable fibrillary low-grade astrocytomas can be treated with up-front CT to improve their neurologic status.
  • This report suggests that benefits of CT on symptoms, survival, and quality of life should be prospectively compared with RT.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Drug Therapy / methods. Nitrosourea Compounds / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16128869.001).
  • [ISSN] 1351-5101
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nitrosourea Compounds
  •  go-up   go-down


11. Arvanitis LD, Koukoulis GK, Kanavaros P: The expression of the O-linked N-acetylglucosamine containing epitope H in the gemistocytic, pilocytic and subependymal giant cell astrocytomas. Oncol Rep; 2009 Sep;22(3):521-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of the O-linked N-acetylglucosamine containing epitope H in the gemistocytic, pilocytic and subependymal giant cell astrocytomas.
  • In normal human brains the epitope H is present mostly to a minority of fibrous astrocytes, whereas it is greatly up-regulated in reactive astrocytes and is increased in well differentiated fibrillary astrocytomas compared to anaplastic astrocytomas and glioblastomas.
  • In this study the expression of the epitope H was investigated in thirty cases of gemistocytic (WHO grade II), pilocytic (WHO grade I), and subependymal giant cell (WHO grade I) astrocytomas using the mAbH with the indirect immunoperoxidase method.
  • The ten cases of gemistocytic astrocytomas revealed an overall high expression pattern.
  • The ten cases of pilocytic astrocytomas revealed a biphasic pattern of epitope H expression.
  • The ten cases of subependynal giant cell astrocytomas occurring in tuberous sclerosis revealed an overall high expression pattern.
  • This study shows that there is high expression of the epitope H in gemistocytic, pilocytic and subependymal giant cell astrocytomas.
  • Collectively considering, the present and our previous data, it appears that there is a spectrum of the expression levels of the epitope H ranging from the high expression in the reactive astrocytes and low grade astrocytomas to the low/null expression in the normal astrocytes and glioblastomas.
  • [MeSH-major] Acetylglucosamine / analysis. Astrocytoma / chemistry. Brain Neoplasms / chemistry. Epitopes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639198.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Epitopes; V956696549 / Acetylglucosamine
  •  go-up   go-down


12. Yan B, Omar FM, Das K, Ng WH, Lim C, Shiuan K, Yap CT, Salto-Tellez M: Characterization of Numb expression in astrocytomas. Neuropathology; 2008 Oct;28(5):479-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of Numb expression in astrocytomas.
  • Given its role in maintaining neural progenitor pools in animal models and its reported role as a tumor suppressor, Numb could potentially contribute to astrocytoma oncogenesis.
  • We characterized Numb expression in both human astrocytoma tissue samples and glioblastoma cell lines.
  • We found that Numb is expressed in all grades of astrocytomas, being predominantly cytoplasmic in higher-grade astrocytomas but nuclear in pilocytic astrocytomas.
  • Numb expression in astrocytomas recapitulates that of progenitor cells during neurodevelopment, and suggests a role for Numb in astrocytoma oncogenesis.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Membrane Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Child. Child, Preschool. Female. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Neuroglia / metabolism. Neurons / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384513.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 0 / Numb protein, human
  •  go-up   go-down


13. López JI, Scheithauer BW, Giannini C, Torp SH: Concurrent solitary fibrous tumor and low-grade fibrillary astrocytoma of the cerebellum. Clin Neuropathol; 2010 Sep-Oct;29(5):301-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent solitary fibrous tumor and low-grade fibrillary astrocytoma of the cerebellum.
  • OBJECTIVE: We report the clinicopathologic features of a solitary fibrous tumor (SFT) having undergone malignant transformation and being intimately associated with a WHO Grade II astrocytoma.
  • CONCLUSION: The biologic basis for the association of SFT and astrocytoma is unknown.
  • Lastly, induction of the glioma by the solitary fibrous tumor, a mechanism invoked to explain the poorly understood "sarcoglioma," deserves consideration.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / epidemiology. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / epidemiology. Solitary Fibrous Tumors / diagnosis. Solitary Fibrous Tumors / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860893.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Arvanitis DL, Arvanitis LD, Panourias IG, Kitsoulis P, Kanavaros P: The expression of the epitope H recognized by the monoclonal antibody H is higher in astrocytomas compared to anaplastic astrocytomas and glioblastomas. Histol Histopathol; 2005 10;20(4):1057-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of the epitope H recognized by the monoclonal antibody H is higher in astrocytomas compared to anaplastic astrocytomas and glioblastomas.
  • In normal human brains epitope H is absent from the overwhelming majority of normal astrocytes and only sparse reactivity is observed, confined mostly to fibrous astrocytes.
  • In the present study we used the mAbH to investigate the immunohistochemical expression of the epitope H in 41 cases of astrocytic tumors including 19 cases of astrocytomas, 8 cases of anaplastic astrocytomas and 14 cases of glioblastomas.
  • Seven out of 19 cases (37%) of astrocytomas showed weak staining, 10 cases (53%) moderate staining and 2 cases (10%) intense staining.
  • Two out of 8 cases (25%) of anaplastic astrocytomas appeared negative, 3 cases (37.5%) showed weak staining and 3 cases (37.5%) moderate staining.
  • There was a statistically significant elevation of the expression of the epitope H in astrocytomas compared to anaplastic astrocytomas and glioblastomas (p=0.047).
  • This could be of interest for predicting the progression of an astrocytic tumor since it is documented that astrocytomas progress to tumors of higher grade of malignancy.
  • [MeSH-major] Antibodies, Monoclonal / metabolism. Astrocytoma / immunology. Epitopes / biosynthesis. Glioblastoma / immunology
  • [MeSH-minor] Animals. Brain Neoplasms / immunology. Brain Neoplasms / pathology. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Rabbits

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16136487.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Epitopes; 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


15. Shuangshoti S, Thorner PS, Ruangvejvorachai P, Saha B, Groshen S, Taylor CR, Malhotra S, Imam SA: J1-31 protein expression in astrocytes and astrocytomas. Neuropathology; 2009 Oct;29(5):521-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] J1-31 protein expression in astrocytes and astrocytomas.
  • J1-31 is one of the astrocytic proteins, the expression of which has not been evaluated in astrocytomas.
  • In the present study, we studied the expression of J1-31 protein in astrocytes and astrocytomas in comparison with GFAP, p53 and Ki-67.
  • Materials consisted of formalin-fixed paraffin-embedded tissue specimens that included five cases of normal brain, 17 of gliosis, 15 of pilocytic astrocytoma (WHO grade I), 26 of low-grade diffuse astrocytoma (WHO grade II), four of anaplastic astrocytoma (WHO grade III), and eight of glioblastoma (WHO grade IV).
  • The antibody showed reactivity with tumor cells in 12/15 (80%) cases of pilocytic astrocytoma, although intensity of staining was generally weaker and more focal than observed in reactive gliosis.
  • J1-31-positive tumor cells were detected in only 9/26 (35%) cases of the low-grade diffuse astrocytoma and none of the cases of anaplastic astrocytoma and glioblastoma.
  • Increasing Ki-67 indices paralleled advancing tumor grades. p53 protein was expressed more commonly in infiltrating astrocytomas compared to pilocytic astrocytoma.
  • In conclusion, down-regulation of J1-31 expression correlates with advancing grade of astrocytomas.
  • [MeSH-major] Astrocytes / metabolism. Astrocytoma / metabolism. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Cytoplasm / metabolism. Down-Regulation. Glial Fibrillary Acidic Protein / metabolism. Glioblastoma / metabolism. Gliosis / metabolism. Humans. Ki-67 Antigen / metabolism. Neoplasm Staging. Tumor Suppressor Protein p53 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019178.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / J1-31 protein, human; 0 / Ki-67 Antigen; 0 / Nerve Tissue Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


16. Ma YH, Mentlein R, Knerlich F, Kruse ML, Mehdorn HM, Held-Feindt J: Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol; 2008 Jan;86(1):31-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of stem cell markers in human astrocytomas of different WHO grades.
  • According to new hypotheses astrocytomas/gliomas either arise from or attract neural stem cells.
  • Because these studies have been performed with single experimental samples mostly from gliomas, we investigated the expression of the stem cell markers CD133/Prominin, Nestin, Sox-2, Musashi-1, CXCR4, Flt-4/VEGFR-3 and CD105/Endoglin in 72 astrocytomas of different WHO-grades and compared it to normal adult human brain.
  • Expression of their mRNA was quantified by quantitative RT-PCR, of their protein by counting immunopositive cells.
  • However, their mean expression was significantly increased in astrocytomas, but this depended on the WHO grade only for CD133, Nestin, Sox-2 and Musashi-1.
  • Confocal microscopy revealed that these markers mostly could be co-stained with glial fibrillary acidic protein, a marker for astoglial cells, but less frequently with the proliferation marker Ki-67/MIB-1.
  • Our results show that most astrocytomas contain considerable portions of cells expressing stem cell markers.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Gene Expression / physiology. Nerve Tissue Proteins / metabolism. Stem Cells / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611714.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Nerve Tissue Proteins
  •  go-up   go-down


17. Varlet P, Jouvet A, Miquel C, Saint-Pierre G, Beuvon F, Daumas-Duport C: [Criteria of diagnosis and grading of oligodendrogliomas or oligo-astrocytomas according to the WHO and Sainte-Anne classifications]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):239-46
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Criteria of diagnosis and grading of oligodendrogliomas or oligo-astrocytomas according to the WHO and Sainte-Anne classifications].
  • According to this approach, the SA classification includes in the category of oligodendrogliomas, the fibrillary or gemistocytic diffuse astrocytomas (WHO grade II) as well as a substantial proportion of astrocytomas WHO grade III, 2) the WHO uses multiple histological criteria for the grading of oligodendrogliomas (grade II versus grade III), including the degree of differentiation, cellular atypia, mitotic activity and necrosis.
  • [MeSH-major] Astrocytoma / classification. Astrocytoma / pathology. Brain Neoplasms / classification. Brain Neoplasms / pathology. Oligodendroglioma / classification. Oligodendroglioma / pathology. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292167.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


18. Reyaz N, Tayyab M, Khan SA, Siddique T: Correlation of glial fibrillary acidic protein (GFAP) with grading of the neuroglial tumours. J Coll Physicians Surg Pak; 2005 Aug;15(8):472-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of glial fibrillary acidic protein (GFAP) with grading of the neuroglial tumours.
  • OBJECTIVE: To determine the distribution of glial fibrillary acidic protein (GFAP) in human neuroglial tumours and its correlation with histologic grading.
  • RESULTS: In positive control only the cell process and perikaryons of fibrous astrocytes was stained.
  • The 35 cases of various grade astrocytoma showed a varying intensity of GFAP staining.
  • Similarly, 3 cases of glioblastoma multiforme, 2 cases of sub-ependymal giant cell astrocytoma, 2 cases of pleomorphic xanthoastrocytoma, 2 out of 4 cases of ependymoma and the case of oligoastrocytoma showed a positive reaction.
  • The stain was more intense over processes than in perikaryons, with the exception of gemistocytic astrocytomas and the giant cells in glioblastoma multiforme, which showed an equally intense stain over perikaryons and processes.
  • GFA protein is specific for glial cells and it is useful to diagnose those glial tumours which are difficult to be identified by heamatoxylin-eosin stain or due to rare or unusual site.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Glial Fibrillary Acidic Protein / metabolism. Glioma / metabolism. Glioma / pathology
  • [MeSH-minor] Astrocytoma / metabolism. Astrocytoma / pathology. Child. Female. Humans. Immunoenzyme Techniques. Immunohistochemistry. Male. Neuroglia / metabolism. Oligodendroglioma / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202357.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


19. Dmytrenko VV, Boĭko OI, Shostak KO, Bilets'kyĭ AV, Malysheva TA, Shamaiev MI, Kliuchka VM, Rozumenko VD, Zozulia IuP, Kavsan VM: [Expression of myelin basic protein and glial fibrillary acidic protein genes in human glial brain tumors]. Tsitol Genet; 2009 Jan-Feb;43(1):28-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of myelin basic protein and glial fibrillary acidic protein genes in human glial brain tumors].
  • Analysis of the expression of genes encoding myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) genes in human glial tumors was carried out for determination of the expression specificity of these genes according to tumor types and their malignancy.
  • Low levels of MBP mRNA in astrocytoma specimens of malignancy grades II-IV and significantly higher levels in perifocal zone adjacent to them have been determined by Northern hybridization.
  • Diffuse astrocytomas and anaplastic astrocytomas are characterized mostly by low level of MBP gene expression and high level of GFAP gene expression, but distinct subtypes of diffuse and anaplastic astrocytomas with high level of MBP gene and low level of GFAP gene expression can be also detected that may be the reflection of different oncogenic pathways.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Gene Expression. Glial Fibrillary Acidic Protein / genetics. Glioma / genetics. Myelin Basic Protein / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19663312.001).
  • [ISSN] 0564-3783
  • [Journal-full-title] T︠S︡itologii︠a︡ i genetika
  • [ISO-abbreviation] Tsitol. Genet.
  • [Language] ukr
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / Glial Fibrillary Acidic Protein; 0 / Myelin Basic Protein; 0 / RNA, Messenger
  •  go-up   go-down


20. Mondal S, Dirks P, Rutka JT: Immunolocalization of fascin, an actin-bundling protein and glial fibrillary acidic protein in human astrocytoma cells. Brain Pathol; 2010 Jan;20(1):190-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunolocalization of fascin, an actin-bundling protein and glial fibrillary acidic protein in human astrocytoma cells.
  • In this report, we investigate fascin in astrocytomas.
  • We show that fascin is expressed in astrocytes and in a panel of human astrocytoma cell lines.
  • Immunofluorescence analysis demonstrates that fascin and the intermediate filament protein, glial fibrillary acidic protein (GFAP), are both expressed in the perinuclear region and within cytoplasmic processes of astrocytes and astrocytoma cells.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / ultrastructure. Carrier Proteins / metabolism. Glial Fibrillary Acidic Protein / metabolism. Microfilament Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19170683.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Cytoskeletal Proteins; 0 / Fluorescent Dyes; 0 / Glial Fibrillary Acidic Protein; 0 / Indoles; 0 / Microfilament Proteins; 146808-54-0 / fascin; 47165-04-8 / DAPI
  •  go-up   go-down


21. Scarabino T, Giannatempo GM, Nemore F, Popolizio T, Stranieri A: Supratentorial low-grade gliomas. Neuroradiology. J Neurosurg Sci; 2005 Sep;49(3):73-6
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this paper we will illustrate morphological aspects of low-grade supratentorial neoplasms, including tumors of neuroepithelial tissue, such as low-grade diffuse fibrillary astrocytomas, and circumscribed astrocytic lesions (pilocytic astrocytoma, pleomorphic xantoastrocytoma and subependymal giant cell astrocytoma).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288189.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 14
  •  go-up   go-down


22. Xu Y, Li WL, Fu L, Gu F, Ma YJ: Slit2/Robo1 signaling in glioma migration and invasion. Neurosci Bull; 2010 Dec;26(6):474-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of Slit2 is at very low levels in pilocytic astrocytoma, fibrillary astrocytoma and glioblastoma, while Robo1 is highly expressed in different grades of gliomas at both mRNA and protein levels.

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21113198.001).
  • [ISSN] 1995-8218
  • [Journal-full-title] Neuroscience bulletin
  • [ISO-abbreviation] Neurosci Bull
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Nerve Tissue Proteins; 0 / Receptors, Immunologic; 0 / Slit homolog 2 protein; 0 / roundabout protein; EC 3.6.5.2 / cdc42 GTP-Binding Protein
  •  go-up   go-down


23. McCarthy BJ, Propp JM, Davis FG, Burger PC: Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology; 2008;30(1):34-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Using CBTRUS data, the incidences (per 100,000 person-years) of oligodendrogliomas (APC = 4.7), mixed gliomas (APC = 3.9) and anaplastic oligodendrogliomas (APC = 12.5) have all increased over time, while the incidences of astrocytoma not otherwise specified (APC = -8.1) and fibrillary astrocytoma (APC = -2.1) have decreased.
  • [MeSH-major] Astrocytoma / epidemiology. Brain Neoplasms / epidemiology. Glioma / epidemiology. Oligodendroglioma / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18259099.001).
  • [ISSN] 1423-0208
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


24. Ohgaki H, Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol; 2005 Jun;64(6):479-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While survival rates for pilocytic astrocytomas were excellent (96% at 10 years), the prognosis of diffusely infiltrating gliomas was poorer, with median survival times (MST) of 5.6 years for low-grade astrocytoma WHO grade II, 1.6 years for anaplastic astrocytoma grade III, and 0.4 years for glioblastoma.
  • TP53 mutations were most frequent in gemistocytic astrocytomas (88%), followed by fibrillary astrocytomas (53%) and oligoastrocytomas (44%), but infrequent (13%) in oligodendrogliomas.
  • LOH 1p/19q typically occurred in tumors without TP53 mutations and were most frequent in oligodendrogliomas (69%), followed by oligoastrocytomas (45%), but were rare in fibrillary astrocytomas (7%) and absent in gemistocytic astrocytomas.
  • [MeSH-major] Astrocytoma. Brain Neoplasms. Loss of Heterozygosity. Oligodendroglioma. Tumor Suppressor Protein p53 / genetics


25. Watanabe T, Katayama Y, Yoshino A, Yachi K, Ohta T, Ogino A, Komine C, Fukushima T: Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol; 2007 Jan;17(1):5-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression.
  • The aim of the present study was to elucidate genetic alterations that are critically involved in astrocytoma progression.
  • We characterized 27 World Health Organization grade II fibrillary astrocytomas which later underwent recurrence or progression, paying specific attention to the CpG island methylation status of critical growth regulatory genes. p14(ARF) and O(6)-methylguanine-DNA methyltransferase (MGMT) hypermethylation represented frequent events (26% and 63%, respectively), which were mutually exclusive except in one case, with alternate or simultaneous methylation of these two genes occurring in 85% of our tumor series.
  • Our findings suggest that p14(ARF) hypermethylation and MGMT hypermethylation constitute distinct molecular pathways of astrocytoma progression, which could differ in biological behavior and clinical outcome.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. CpG Islands / physiology. Neoplasm Recurrence, Local / metabolism. O(6)-Methylguanine-DNA Methyltransferase / metabolism. Tumor Suppressor Protein p14ARF / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493032.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


26. Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quiñones-Hinojosa A: Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg; 2010 Jan;112(1):10-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 191 consecutive patients with low-grade gliomas in this series (89 fibrillary astrocytomas, 89 oligodendrogliomas, and 13 mixed gliomas), 83 (43%) and 44 (23%) experienced tumor recurrence and malignant degeneration at last follow-up, respectively.
  • Independent factors associated with malignant degeneration were fibrillary astrocytoma pathology (RR 1.800, 95% CI 1.008-4.928, p = 0.04), tumor size (RR 1.086, 95% CI 1.044-1.358, p = 0.04), and gross-total resection (RR 0.526, 95% CI 0.221-1.007, p = 0.05).
  • [MeSH-minor] Adult. Astrocytoma / pathology. Astrocytoma / surgery. Disease Progression. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Multivariate Analysis. Neoplasm Staging. Oligodendroglioma / pathology. Oligodendroglioma / surgery. Proportional Hazards Models. Retrospective Studies. Risk Factors. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361270.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Pareés I, Alonso J, Rovira A, Martínez E, Montalban X: [Diffuse astrocytoma presenting as an optic-spinal syndrome]. Rev Neurol; 2009 Apr 1-15;48(7):354-6
Genetic Alliance. consumer health - Diffuse Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffuse astrocytoma presenting as an optic-spinal syndrome].
  • [Transliterated title] Síndrome opticomedular como forma de presentación de un astrocitoma difuso.
  • INTRODUCTION: Spinal cord involvement is a rare presentation of grade II astrocytomas.
  • A patient with an optic-spinal syndrome due to a fibrillary astrocytoma is described.
  • A new MRI with spectroscopy revealed an infiltrative lesion involving the right frontal lobe, optic chiasm, internal capsule, brainstem and cervical spinal cord, which was suggestive of low-grade astrocytoma.
  • Brain biopsy confirmed the diagnosis of diffuse fibrillary astrocytoma.
  • [MeSH-major] Astrocytoma. Demyelinating Diseases. Optic Neuritis. Spinal Cord / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19319816.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Oligoclonal Bands
  •  go-up   go-down


28. Zhang S, Wang X, Zhang Z, Chen Y: Tanycytic ependymoma arising from the right lateral ventricle: a case report and review of the literature. Neuropathology; 2008 Aug;28(4):427-32
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, the tumor composed of nuclear dense zones consisting of a cluster of spindle cells and fibrillary zones consisting of streaming of cell processes.
  • Histological differential diagnosis includes spindle-shaped neuroepithelial tumors, such as pilocytic astrocytoma, fibrillary astrocytoma and schwannoma.

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312548.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


29. Shukla B, Agarwal S, Suri V, Pathak P, Sharma MC, Gupta D, Sharma BS, Suri A, Halder A, Sarkar C: Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. Neurol India; 2009 Sep-Oct;57(5):559-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glial fibrillary acidic protein (GFAP), EGFR and p53 were assessed by immunohistochemistry.
  • RESULTS: Glial fibrillary acidic protein immunopositivity was observed in oligodendrogliomas within minigemistocytes and gliofibrillary oligodendrocytes as perinuclear homogenous blobs.
  • Astrocytomas and the astrocytic component of oligoastrocytomas showed a diffuse fibrillary type of staining.
  • None of the astrocytomas including two pediatric cases showed this alteration (P < 0.05).
  • p53 was expressed in 57.1% of astrocytomas (8/14), 33% of mixed oligoastrocytomas (3/9) and 10% of oligodendrogliomas (2/20).
  • In contrast, all astrocytomas (Grade II and III) were EGFR negative.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosomes, Human, Pair 19. In Situ Hybridization, Fluorescence / methods. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Male. Middle Aged. Receptor, Epidermal Growth Factor / metabolism. Retrospective Studies. Tumor Suppressor Protein p53 / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934553.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


30. Massimino M, Spreafico F, Riva D, Biassoni V, Poggi G, Solero C, Gandola L, Genitori L, Modena P, Simonetti F, Potepan P, Casanova M, Meazza C, Clerici CA, Catania S, Sardi I, Giangaspero F: A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol; 2010 Oct;100(1):65-71
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnoses were clinical in 13 cases and histological in 24, and comprised: pilocytic astrocytoma (17), ganglioglioma (3), pilomyxoid astrocytoma (2), and fibrillary astrocytoma (2).


31. Inoue T, Ogasawara K, Kumabe T, Jokura H, Watanabe M, Ogawa A: Minute glioma identified by 3.0 Tesla magnetic resonance spectroscopy--case report. Neurol Med Chir (Tokyo); 2005 Feb;45(2):108-11
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological diagnosis was fibrillary astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Spectroscopy

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15722611.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


32. Tatevossian RG, Tang B, Dalton J, Forshew T, Lawson AR, Ma J, Neale G, Shurtleff SA, Bailey S, Gajjar A, Baker SJ, Sheer D, Ellison DW: MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathol; 2010 Dec;120(6):731-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies of genetic abnormalities in pediatric low-grade gliomas (LGGs) have focused on activation of the ERK/MAPK pathway by KIAA1549-BRAF gene fusions in the majority of pilocytic astrocytomas (PAs) and by rare mutations in elements of the pathway across histopathologically diverse LGGs.
  • The LGG cohort included 34 PAs and 23 diffuse gliomas; fibrillary astrocytomas (n = 14), oligodendroglial tumors (n = 7), and angiocentric gliomas (n = 2).
  • Novel MYB amplifications that upregulate MYB RNA and protein expression were demonstrated in 2/14 diffuse astrocytomas.
  • Increased expression of MYB was demonstrated by quantitative RT-PCR and immunohistochemistry.
  • MYB upregulation at the protein level was demonstrated in a proportion of diffuse LGGs (60%), pilocytic astrocytomas (41%), and HGGs (19%), but abnormalities at the genomic level were only a feature of diffuse gliomas.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] J Pathol. 2009 Jun;218(2):172-81 [19373855.001]
  • [Cites] Pediatr Neurosurg. 2003 Sep;39(3):114-21 [12876389.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):721-9 [15195090.001]
  • [Cites] BMC Genomics. 2004 May 31;5(1):33 [15169551.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):29519-27 [15105423.001]
  • [Cites] Cell. 1979 Oct;18(2):375-90 [227607.001]
  • [Cites] Nature. 1988 Oct 27;335(6193):835-7 [3185713.001]
  • [Cites] Cell. 1991 May 17;65(4):677-89 [1709592.001]
  • [Cites] Cell Growth Differ. 1996 Jul;7(7):961-7 [8809414.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3135-9 [9242439.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2321-32 [9404710.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3017-33 [10378697.001]
  • [Cites] Cancer Biol Ther. 2009 Jan;8(1):4-10 [19164945.001]
  • [Cites] N Engl J Med. 2009 May 21;360(21):2248; author reply 2249 [19458374.001]
  • [Cites] Oncogene. 2009 May 21;28(20):2119-23 [19363522.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):449-58 [19016743.001]
  • [Cites] Neuro Oncol. 2009 Aug;11(4):403-13 [19033157.001]
  • [Cites] Cancer Biol Ther. 2008 Nov;7(11):1758-64 [18708755.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18740-4 [19841262.001]
  • [Cites] Cancer. 2009 Dec 15;115(24):5761-70 [19813274.001]
  • [Cites] Cancer Res. 2009 Dec 15;69(24):9157-9 [19996293.001]
  • [Cites] J Cell Physiol. 2010 Mar;222(3):509-14 [19937730.001]
  • [Cites] Cancer Res. 2010 Jan 15;70(2):512-9 [20068183.001]
  • [Cites] Cold Spring Harb Protoc. 2009 Apr;2009(4):pdb.prot5199 [20147142.001]
  • [Cites] Acta Neuropathol. 2010 May;119(5):641-9 [20044755.001]
  • [Cites] Acta Neuropathol. 2010 Aug;120(2):271-3 [20454969.001]
  • [Cites] Cell Cycle. 2010 Aug 1;9(15):2986-95 [20647765.001]
  • [Cites] Clin Cancer Res. 2010 Oct 1;16(19):4722-31 [20702610.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5323-8 [11034064.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7404-7 [11606370.001]
  • [Cites] Neuro Oncol. 2010 Jul;12(7):621-30 [20156809.001]
  • [Cites] Stem Cells. 2008 Jan;26(1):173-81 [17901403.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3047-55 [10378700.001]
  • [Cites] Acta Neuropathol. 2005 Apr;109(4):387-92 [15739101.001]
  • [Cites] Adv Anat Pathol. 2005 Jul;12(4):180-94 [16096380.001]
  • [Cites] Immunity. 2005 Sep;23(3):275-86 [16169500.001]
  • [Cites] J Neurosurg. 2006 Apr;104(4):542-50 [16619658.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):549-61 [16783165.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(13):2064-80 [16919771.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):682-9 [17308273.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):113-23 [17327574.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Nat Genet. 2007 May;39(5):593-5 [17435759.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1251-61 [17452517.001]
  • [Cites] Cell. 2007 Oct 5;131(1):146-59 [17923094.001]
  • [Cites] Br J Cancer. 2007 Dec 3;97(11):1588-94 [17987032.001]
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1709-18 [18059228.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] Brain Tumor Pathol. 2006 Apr;23(1):41-7 [18095118.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] Nat Rev Cancer. 2008 Jul;8(7):523-34 [18574464.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] Blood. 2009 Jan 15;113(3):505-16 [18818396.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 May;62(5):530-7 [12769192.001]
  • (PMID = 21046410.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA096832-07; United States / NCI NIH HHS / CA / P01 CA096832; United States / NCI NIH HHS / CA / P01 CA096832-07; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Oncogene Proteins v-myb
  • [Other-IDs] NLM/ NIHMS266504; NLM/ PMC3066475
  •  go-up   go-down


33. Terakawa Y, Morino M, Yamagata T, Ohata K: Extradural pneumatocele after temporal craniotomy: case report. Neurol Med Chir (Tokyo); 2008 Dec;48(12):576-7
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 22-year-old female first presented with a fibrillary astrocytoma in the left temporal region manifesting as complex partial seizure.
  • [MeSH-minor] Arachnoid Cysts / complications. Arachnoid Cysts / surgery. Astrocytoma / complications. Astrocytoma / surgery. Brain Neoplasms / complications. Brain Neoplasms / surgery. Epilepsy, Complex Partial / etiology. Epilepsy, Temporal Lobe / etiology. Female. Humans. Pressure. Temporal Lobe / surgery. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106498.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Rousseau A, Nutt CL, Betensky RA, Iafrate AJ, Han M, Ligon KL, Rowitch DH, Louis DN: Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol; 2006 Dec;65(12):1149-56
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on data from the literature and from expression microarrays, we selected molecules relevant to gliogenesis and glial lineage specificity and then used immunohistochemistry to assess expression of these molecules in 55 diffuse gliomas, including 8 biphasic oligoastrocytomas, 21 oligodendrogliomas (all with 1p/19qloss), 21 astrocytomas, and 5 glioblastomas.
  • GFAP, YKL-40, and ApoE reliably distinguished grade II-III oligodendrogliomas from grade II-IV astrocytomas (p < 0.0001, p = 0.002, and p < 0.0001, respectively).
  • Among the oligodendroglial lineage markers (Olig2, Sox10, ASCL1, and NKX2-2), ASCL1 and NKX2-2 displayed significantly different immunostaining between oligodendrogliomas and astrocytomas (p = 0.017 and 0.004, respectively), but none clearly differentiated between the 2 glial populations of oligoastrocytomas.
  • In addition to GFAP, therefore, YKL-40, ApoE, ASCL1, and NKX2-2 represent promising tumor cell markers to distinguish oligodendrogliomas from astrocytomas.
  • [MeSH-minor] Adipokines. Apolipoproteins E / analysis. Apolipoproteins E / metabolism. Astrocytoma / diagnosis. Astrocytoma / genetics. Astrocytoma / metabolism. Basic Helix-Loop-Helix Transcription Factors / analysis. Basic Helix-Loop-Helix Transcription Factors / metabolism. Diagnosis, Differential. Glial Fibrillary Acidic Protein / analysis. Glial Fibrillary Acidic Protein / metabolism. Glycoproteins / analysis. Glycoproteins / metabolism. Homeodomain Proteins / analysis. Homeodomain Proteins / metabolism. Humans. Immunohistochemistry. Lectins. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics. Oligodendroglioma / metabolism. Predictive Value of Tests. Transcription Factors / analysis. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17146289.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 57683; United States / NCI NIH HHS / CA / CA 95616
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ASCL1 protein, human; 0 / Adipokines; 0 / Apolipoproteins E; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / CHI3L1 protein, human; 0 / Glial Fibrillary Acidic Protein; 0 / Glycoproteins; 0 / Homeodomain Proteins; 0 / Lectins; 0 / Nkx-2.2 homedomain protein; 0 / Transcription Factors; 0 / apolipoprotein E1
  •  go-up   go-down


35. Mertsch S, Schmitz N, Jeibmann A, Geng JG, Paulus W, Senner V: Slit2 involvement in glioma cell migration is mediated by Robo1 receptor. J Neurooncol; 2008 Mar;87(1):1-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because similar molecular mechanisms may be utilized in glioma cell invasion and neuroblast migration, we studied the expression of Slit2 and its transmembrane receptor Robo1 as well as their functional role in migration in glioma cells. qRT-PCR and immunohistochemistry of human specimens revealed that Slit2 was distinctly expressed by non-neoplastic neurons, but at only very low levels in fibrillary astrocytoma and glioblastoma.

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17968499.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Nerve Tissue Proteins; 0 / RNA, Small Interfering; 0 / Receptors, Immunologic; 0 / Slit homolog 2 protein; 0 / roundabout protein
  •  go-up   go-down


36. Colin C, Baeza N, Tong S, Bouvier C, Quilichini B, Durbec P, Figarella-Branger D: In vitro identification and functional characterization of glial precursor cells in human gliomas. Neuropathol Appl Neurobiol; 2006 Apr;32(2):189-202
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human gliomas including astrocytomas and oligodendrogliomas are defined as being composed of neoplastic astrocytes and oligodendrocytes respectively.
  • We have set up explant cultures from pilocytic astrocytomas, glioblastomas and oligodendrogliomas and studied antigens that characterize glial lineage, from the precursor cells (glial restricted precursors and oligodendrocyte-type2-astrocyte/oligodendrocyte precursor cells expressing the A2B5 ganglioside) to the differentiated cells (oligodendrocyte and type-1 and type-2 astrocytes).
  • In pilocytic astrocytomas, very few migrating cells are dividing and can differentiate in type-2 astrocytes or towards the oligodendrocyte lineage.
  • In glioblastomas, most migrating cells are dividing, express A2B5 or glial fibrillary acid protein (GFAP) and can generate oligodendrocytes and type-1 and type-2 astrocytes in appropriate medium.
  • Therefore, pilocytic astrocytomas contain slowly dividing oligodendrocyte-type2-astrocyte/oligodendrocyte precursor cells in keeping with their benign behaviour whereas both glioblastomas and oligodendrogliomas contain neoplastic glial restricted precursor cells.
  • [MeSH-minor] Adult. Cell Differentiation. Cell Lineage. Cell Movement. Child. Child, Preschool. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. In Vitro Techniques. Middle Aged


37. Jalali R, Dutta D, Kamble R, Gupta T, Munshi A, Sarin R, Dinshaw K: Prospective assessment of activities of daily living using modified Barthel's Index in children and young adults with low-grade gliomas treated with stereotactic conformal radiotherapy. J Neurooncol; 2008 Dec;90(3):321-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULT: The patient population consisted of 38 patients (male 29, female 9) with a diagnosis of residual or progressive low-grade glioma (pilocytic astrocytoma in 27, fibrillary astrocytoma in 5, ependymoma in 4, and oligodendroglioma and pleomorphic xanthoastrocytoma in 1 each).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18704269.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


38. Porter A, Lyons MK, Wingerchuk DM, Bosch EP: Spinal cord astrocytoma presenting as "idiopathic" intracranial hypertension. Clin Neurol Neurosurg; 2006 Dec;108(8):787-9
Genetic Alliance. consumer health - Intracranial Hypertension.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord astrocytoma presenting as "idiopathic" intracranial hypertension.
  • Open biopsy confirmed a grade 3 fibrillary astrocytoma.
  • The suspected mechanisms of spinal tumors causing increased intracranial pressure are reviewed as well as three other cases of spinal astrocytomas previously reported in the literature that presented with papilledema and increased intracranial pressure without hydrocephalus.
  • [MeSH-major] Astrocytoma / diagnosis. Pseudotumor Cerebri / etiology. Spinal Cord Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16298472.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


39. Suzuki T, Izumoto S, Fujimoto Y, Maruno M, Ito Y, Yoshimine T: Clinicopathological study of cellular proliferation and invasion in gliomatosis cerebri: important role of neural cell adhesion molecule L1 in tumour invasion. J Clin Pathol; 2005 Feb;58(2):166-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: In patients with gliomatosis cerebri (GC), glial fibrillary acidic protein (GFAP) positive cells invade the entire brain, particularly the white matter.
  • CONCLUSION: The strong expression of L1 in patients with GC and its poor expression in the 20 patients with other types of glioma, including those with GFAP positive gemistocytic astrocytomas, suggest that L1 expression may play a role in the histogenesis of GC.
  • [MeSH-minor] Adult. Aged. Antibodies, Neoplasm / analysis. Astrocytoma / chemistry. Astrocytoma / pathology. Brain Chemistry. Cell Division / physiology. Female. Glial Fibrillary Acidic Protein / analysis. Glioblastoma / chemistry. Glioblastoma / pathology. Humans. Immunohistochemistry / methods. Ki-67 Antigen / immunology. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biol Cell. 2001 Sep;12(9):2699-710 [11553709.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):2935-40 [9679949.001]
  • [Cites] Lancet. 2003 Sep 13;362(9387):869-75 [13678974.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):28880-8 [15128735.001]
  • [Cites] Nature. 1983 Sep 29-Oct 5;305(5933):427-30 [6621692.001]
  • [Cites] Nature. 1985 Aug 22-28;316(6030):725-8 [2412126.001]
  • [Cites] Clin Neuropathol. 1985 Jul-Aug;4(4):135-48 [4053456.001]
  • [Cites] J Cell Biol. 1987 Oct;105(4):1893-9 [2444603.001]
  • [Cites] Development. 1988 Apr;102(4):639-55 [3048970.001]
  • [Cites] Surg Neurol. 1991 Dec;36(6):431-40 [1759182.001]
  • [Cites] J Biol Chem. 1992 May 25;267(15):10752-8 [1587850.001]
  • [Cites] Neuroreport. 1992 Jun;3(6):481-4 [1391752.001]
  • [Cites] Neurosci Lett. 1992 Sep 14;144(1-2):221-4 [1436706.001]
  • [Cites] J Neurosci. 1993 Nov;13(11):4764-75 [8229197.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Mol Cell Biol. 1995 Apr;15(4):1942-52 [7891688.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1440-4 [8640837.001]
  • [Cites] J Clin Pathol. 1998 Jan;51(1):13-7 [9577364.001]
  • [Cites] J Cell Biol. 2001 Nov 12;155(4):661-73 [11706054.001]
  • (PMID = 15677537.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Neural Cell Adhesion Molecule L1
  • [Other-IDs] NLM/ PMC1770574
  •  go-up   go-down


40. Stokland T, Liu JF, Ironside JW, Ellison DW, Taylor R, Robinson KJ, Picton SV, Walker DA: A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol; 2010 Dec;12(12):1257-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From the cohort of 798 patients, 639 patients were eligible, with a median age 6.71 years (0.26-16.75 years); 49% were males; 15.9% had neurofibromatosis type 1, 63.7% pilocytic astrocytoma, 5.9% fibrillary astrocytoma, 4.2% mixed neuronal-glial tumors, and 3.6% others; 21.1% were diagnosed clinically.
  • There was a significant association between age and site (P < .001) and extent of tumor resection and site (P < .001).
  • Multivariate analysis identified young age, fibrillary astrocytoma, and extent of surgical resection as significant independent risk factors for progression.
  • In conclusion, the influence of age and anatomical site upon the risk of tumor progression suggests that these factors strongly influence tumor behavior for the majority of pilocytic tumors.
  • Age <1 year and 1-5 years, fibrillary histology, completeness of resection, and chiasmatic location are candidates for stratification in future studies.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 2005 Nov;21(11):940-4 [16044344.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):449-58 [19016743.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12):1807-16 [16809032.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Jul;29(7):465-70 [17609624.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8588-95 [17875698.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):245-50 [18386785.001]
  • [Cites] Pediatr Neurosurg. 2008;44(4):324-8 [18504420.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • [Cites] Br J Radiol. 2008 Oct;81(970):761-6 [18796556.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] J Pathol. 2009 Jun;218(2):172-81 [19373855.001]
  • [Cites] Oncogene. 2009 May 21;28(20):2119-23 [19363522.001]
  • [Cites] BMJ. 2001 Jul 28;323(7306):224-8 [11473921.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):503-11 [11585322.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3155-64 [11753995.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2951-8 [12089224.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4209-16 [12377964.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1084-92 [12569610.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):807-12 [12788189.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4572-8 [14673044.001]
  • [Cites] J Neurosurg. 1984 Oct;61(4):665-73 [6470776.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):215-25 [8420869.001]
  • [Cites] JAMA. 1994 Jul 20;272(3):234-7 [8022043.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]
  • [Cites] J Neurosurg. 1997 May;86(5):747-54 [9126887.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2792-9 [9256121.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3129-40 [9294476.001]
  • [Cites] Pediatr Neurosurg. 1998 Jul;29(1):23-8 [9755308.001]
  • [Cites] Childs Nerv Syst. 1998 Nov;14(11):636-48 [9840364.001]
  • [Cites] J Child Neurol. 1999 Jun;14(6):352-6 [10385841.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):38-44 [10469435.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1061-8 [10515229.001]
  • [Cites] Klin Padiatr. 2004 Nov-Dec;216(6):331-42 [15565548.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):481-8 [15905853.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1358-63 [16470608.001]
  • (PMID = 20861086.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3018938
  •  go-up   go-down


41. Oshiro S, Tsugu H, Komatsu F, Abe H, Onishi H, Ohmura T, Iwaasa M, Sakamoto S, Fukushima T: Quantitative assessment of gliomas by proton magnetic resonance spectroscopy. Anticancer Res; 2007 Nov-Dec;27(6A):3757-63
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Eight patients with histologically verified gliomas, comprising 2 cases with glioblastoma multiforme (GBM, grade 4), 5 cases with anaplastic oligodendroglioma (AO, grade 3; high-grade glioma), and 1 case with fibrillary astrocytoma (FA, grade 2; low-grade glioma) were evaluated using the 1H-MRS protocol following conventional MR imaging, diffusion-weighted imaging (DWI), and perfusion-weighted imaging (PWI) preoperatively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970039.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


42. Schiffer D, Manazza A, Tamagno I: Nestin expression in neuroepithelial tumors. Neurosci Lett; 2006 May 29;400(1-2):80-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As an early marker of differentiation, Nestin is almost not expressed in diffuse astrocytomas, variably expressed in anaplastic astrocytomas and strongly and irregularly expressed in glioblastomas.
  • Negative in oligodendrogliomas, it stains ependymomas and shows a gradient of expression in pilocytic astrocytomas.
  • [MeSH-minor] Blotting, Western / methods. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry / methods. Ki-67 Antigen / metabolism. Microscopy, Confocal / methods. Nestin. Vimentin / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16529857.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Ki-67 Antigen; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Vimentin
  •  go-up   go-down


43. de Chadarévian JP, Halligan GE, Reddy G, Bertrand L, Pascasio JM, Faerber EN, Katsetos CD: Glioneuronal phenotype in a diencephalic pilomyxoid astrocytoma. Pediatr Dev Pathol; 2006 Nov-Dec;9(6):480-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioneuronal phenotype in a diencephalic pilomyxoid astrocytoma.
  • We report the presence of divergent populations of cells in a hypothalamic/chiasmatic pilomyxoid astrocytoma of an 11-month-old male, exhibiting differential immunohistochemical localizations for glial fibrillary acidic protein (GFAP) and synaptophysin.
  • Our results indicate that a subset of the so-called pilomyxoid astrocytomas of the hypothalamic/chiasmatic region may represent phenotypically mixed glioneuronal neoplasms distinct from the pilocytic astrocytomas.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Ganglioglioma / pathology. Hypothalamus / pathology
  • [MeSH-minor] Astrocytes / ultrastructure. Glial Fibrillary Acidic Protein / analysis. Humans. Immunoenzyme Techniques. Infant. Magnetic Resonance Imaging. Male. Microscopy, Confocal. Microscopy, Electron, Transmission. Neurons / ultrastructure. Phenotype. Synaptophysin / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163791.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Synaptophysin
  •  go-up   go-down


44. Pipp I, Wagner L, Rössler K, Budka H, Preusser M: Secretagogin expression in tumours of the human brain and its coverings. APMIS; 2007 Apr;115(4):319-26
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We detected no secretagogin expression in fibrillary astrocytoma, pilocytic astrocytoma, DNT, pineocytoma, pineoblastoma, subependymal giant cell astrocytoma (SEGA), atypical teratoid/rhabdoid tumour (AT/RT), or primary central nervous system lymphoma (PCNSL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504298.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / SCGN protein, human; 0 / Secretagogins
  •  go-up   go-down


45. Lymbouridou R, Soufla G, Chatzinikola AM, Vakis A, Spandidos DA: Down-regulation of K-ras and H-ras in human brain gliomas. Eur J Cancer; 2009 May;45(7):1294-303
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the mutational, mRNA and protein expression profile of the ras genes in 21 glioblastomas multiforme (grade IV), four fibrillary astrocytoma (grade II), four anaplastic astrocytoma (grade III) and 15 normal specimens.
  • K-, H- and N-ras transcript levels were determined by real-time RT-PCR and mutational status by PCR-restriction fragment length polymorphism (RFLP) and direct sequencing. p21 protein was evaluated by Western blot analysis.
  • [MeSH-minor] Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Astrocytoma / mortality. Blotting, Western / methods. Case-Control Studies. Codon. Female. Gene Expression. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / mortality. Humans. Male. Middle Aged. Oncogene Protein p21(ras) / analysis. Oncogene Protein p21(ras) / metabolism. Polymorphism, Restriction Fragment Length. Reverse Transcriptase Polymerase Chain Reaction / methods. Statistics, Nonparametric. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179066.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon; EC 3.6.5.2 / Oncogene Protein p21(ras)
  •  go-up   go-down


46. Julow J, Szeifert GT, Bálint K, Nyáry I, Nemes Z: The role of microglia/macrophage system in the tissue response to I-125 interstitial brachytherapy of cerebral gliomas. Neurol Res; 2007 Apr;29(3):233-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Out of a series of 60 cases with cerebral astrocytomas and other brain tumors treated with I-125 interstitial brachytherapy, autopsy materials were available in ten cases 0.75 and 60 months after irradiation.
  • Six months after the I-125 isotope treatment, a reactive zone developed: a microglial rim around the necrosis tissue, and a broad area of proliferating vessels and glial fibrillary acidic protein (GFAP) positive astroglial cells which contained CD68 positive activated microglial and macrophage cells.
  • [MeSH-minor] Antigens, CD / metabolism. Antigens, CD31 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Iodine Radioisotopes / therapeutic use. Male. Middle Aged. Phosphoglucomutase / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509220.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Glial Fibrillary Acidic Protein; 0 / Iodine Radioisotopes; EC 5.4.2.2 / PGM1 protein, human; EC 5.4.2.2 / Phosphoglucomutase
  •  go-up   go-down


47. Khanlou N, Mathern GW, Mitchell WG, Salamon N, Pope WB, Yong WH, Vinters HV: Cortical dysplasia with prominent Rosenthal fiber formation in a case of intractable pediatric epilepsy. Hum Pathol; 2009 Aug;40(8):1200-4
Hazardous Substances Data Bank. CARBAMAZEPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rosenthal fiber proliferation may represent a reactive process, are frequent in pilocytic astrocytomas, and are a defining feature of Alexander disease.
  • [MeSH-minor] Anticonvulsants / therapeutic use. Brain / pathology. Carbamazepine / analogs & derivatives. Carbamazepine / therapeutic use. Child, Preschool. Diagnosis, Differential. Glial Fibrillary Acidic Protein / genetics. Glial Fibrillary Acidic Protein / metabolism. Humans. Magnetic Resonance Imaging. Male. Polymorphism, Single Nucleotide / genetics. Sequence Analysis, DNA. Treatment Outcome

  • Genetic Alliance. consumer health - Epilepsy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXCARBAZEPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19427021.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS38992
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Glial Fibrillary Acidic Protein; 33CM23913M / Carbamazepine; VZI5B1W380 / oxcarbazepine
  •  go-up   go-down


48. Porto L, Kieslich M, Franz K, Lehrbecher T, Pilatus U, Hattingen E: Proton magnetic resonance spectroscopic imaging in pediatric low-grade gliomas. Brain Tumor Pathol; 2010 Oct;27(2):65-70
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our purpose was to investigate whether in vivo proton magnetic resonance spectroscopic imaging, using normalized concentrations of total choline (tCho) and total creatine (tCr), can differentiate between WHO grade I pilocytic astrocytoma (PA) and diffuse, fibrillary WHO grade II astrocytoma (DA) in children.
  • Data from 16 children with astrocytomas (11 children with PA and 5 children with DA) were evaluated retrospectively.
  • MRS was performed before treatment in all patients with histologically proven low-grade astrocytomas.
  • We concluded that choline as a single parameter is not reliable in the differential diagnosis of low-grade astrocytomas in children.
  • [MeSH-minor] Adolescent. Astrocytoma / diagnosis. Astrocytoma / metabolism. Astrocytoma / pathology. Brain / pathology. Child. Child, Preschool. Choline / metabolism. Creatine / metabolism. Diagnosis, Differential. Female. Humans. Infant. Infratentorial Neoplasms / metabolism. Infratentorial Neoplasms / pathology. Magnetic Resonance Spectroscopy. Male. Supratentorial Neoplasms / metabolism. Supratentorial Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046307.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


49. Yue WY, Chen ZP: Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem; 2005 Aug;53(8):997-1002
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does vasculogenic mimicry exist in astrocytoma?
  • It is unknown whether a similar VM phenomenon exists in astrocytoma.
  • The present study was to examine 45 astrocytomas (including World Health Organization grade II 15 cases, grade III 15 cases, and grade IV 15 cases) by CD34 endothelial marker periodic acid-Schiff (PAS) dual staining to see if VM existing in these tumors.
  • PAS-positive pattern of VM was found in two grade IV astrocytomas.
  • Furthermore, in astrocytoma, especially glioblastoma, focus of anaplastic tumor cells appeared with CD34 expression, whereas some tumor cells lost glial fibrillary acid protein expression.
  • It is assumed that genetically deregulated tumor cells in astrocytoma could lose the astrocyte-specific protein and express inappropriate markers not expected in cells of astrocyte lineage.
  • The present results suggest that VM phenomenon exists in some malignant astrocytoma.
  • [MeSH-major] Astrocytoma / blood supply. Brain Neoplasms / blood supply

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923371.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 0 / Coloring Agents; 0 / Schiff Bases; 10450-60-9 / Periodic Acid
  •  go-up   go-down


50. Su W, Xing R, Guha A, Gutmann DH, Sherman LS: Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging. Glia; 2007 May;55(7):723-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis 1 (NF1) is a common genetic disease that predisposes patients to peripheral nerve tumors and central nervous system (CNS) abnormalities including low-grade astrocytomas and cognitive disabilities.
  • Using mice with glial fibrillary acidic protein (GFAP)-targeted Nf1 loss (Nf1(GFAP)CKO mice), we found that Nf1(-/-) astrocytes proliferate faster and are more invasive than wild-type astrocytes.
  • [MeSH-major] Aging / metabolism. Axons / metabolism. Brain / metabolism. Glial Fibrillary Acidic Protein / genetics. Neurofibromin 1 / genetics. Proto-Oncogene Proteins c-met / metabolism

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17348023.001).
  • [ISSN] 0894-1491
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR 0163
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Glial Fibrillary Acidic Protein; 0 / Neurofibromin 1; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


51. Hlobilkova A, Ehrmann J, Sedlakova E, Krejci V, Knizetova P, Fiuraskova M, Kala M, Kalita O, Kolar Z: Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression? Neoplasma; 2007;54(4):334-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent alterations found in astrocytomas are two major groups of signaling proteins: the cell cycle and the growth factor-regulated signaling pathways.
  • The aim of our study was to detect changes in expression of the following proteins: the tumor suppressors PTEN, p53, and p21Waf1/Cip1, glial fibrillary acidic protein (GFAP, as a marker of astroglial differentiation), the phosphorylated form of protein kinase B/Akt (PKB/Akt), which is downstream to the epidermal growth factor receptor (EGFR), and MDM2, which degrades p53.
  • Paraffin-embedded astrocytoma tissue samples from 89 patients were divided into low grade (grade I-II; 42 samples) and high grade astrocytomas (grade III-IV; 47 samples).
  • EGFR protein was detected in 29 % of low grade and in 60 % of high grade astrocytomas.
  • The expression of phosphorylated PKB/Akt was found in roughly the same proportions: in 86% of low grade and in 79% of high grade astrocytomas.
  • PTEN was not found in most of astrocytomas, 64% of low grade and 74% of high grade tumors showed no PTEN staining.
  • Overexpression of the mutated form of p53 or loss of p53 expression, however, was found in about 63% in both groups of astrocytomas with no differences between them.
  • GFAP positive tumor cells were detected in only 50% of low grade, and 32% of high grade astrocytomas.
  • We conclude that EGFR expression increases with astrocytoma grading.
  • The alteration of p53 supports the finding that the cell cycle regulation is also disrupted during development of astrocytomas.
  • EGFR is one of the factors, which drives the progression of astrocytomas from low to high grade stage.
  • [MeSH-major] Astrocytoma / metabolism. Cell Cycle. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / metabolism. Humans. Male. Middle Aged. Mutation / genetics. Oligodendroglioma / metabolism. Oligodendroglioma / pathology. PTEN Phosphohydrolase / metabolism. Phosphorylation. Proto-Oncogene Proteins c-mdm2 / metabolism. Receptor, Epidermal Growth Factor / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822324.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Glial Fibrillary Acidic Protein; 0 / Tumor Suppressor Protein p53; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


52. Menon G, Nair S, Sudhir J, Rao BR, Krishnakumar K: Bilateral thalamic lesions. Br J Neurosurg; 2010 Oct;24(5):566-71
MedlinePlus Health Information. consumer health - Hydrocephalus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsy confirmation was possible in six patients and histopathology was suggestive of low grade fibrillary astrocytoma in all six patients.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20536292.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


53. Machado CM, Ikemori RY, Zorzeto TQ, Nogueira AC, Barbosa SD, Savino W, Schenka AA, Vassallo J, Heinrich JK, Boetcher-Luiz F, Verinaud L: Characterization of cells recovered from the xenotransplanted NG97 human-derived glioma cell line subcultured in a long-term in vitro. BMC Cancer; 2008;8:291
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our laboratory settled the NG97 cell line derived from a human astrocytoma grade III, which started to develop and express important phenotypical characteristics of an astrocytoma grade IV after injection in the flank of nude mice.
  • Astrocytomas are extremely aggressive malignancies of the Central Nervous System (CNS) and account for 46% of all primary malignant brain tumors.
  • RESULTS: Results showed that NG97(ht) had an decrease in doubling time through sub cultivation, which was characterized by a converse modulation between the expression of glial fibrillary acidic protein (GFAP) and vimentin.
  • Our results emphasize important queries about astrocytomas tumor progression.
  • [MeSH-major] Astrocytoma / pathology
  • [MeSH-minor] Animals. Antigens, CD29 / biosynthesis. Cell Growth Processes / physiology. Cell Line, Tumor. Chromosome Aberrations. Flow Cytometry. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Transplantation, Heterologous. Vimentin / biosynthesis

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1992 Jul;201(1):1-7 [1612114.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1998 Jun;34(6):455-62 [9661048.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5158-65 [8221651.001]
  • [Cites] Cell Mol Neurobiol. 2005 Aug;25(5):929-41 [16133944.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8274-9 [16912208.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(4):661-5 [17141551.001]
  • [Cites] Sci Am. 2007 May;296(5):52-9 [17500414.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):8995-9000 [17517657.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):133-48 [17874037.001]
  • [Cites] Brain. 2007 Dec;130(Pt 12):3336-41 [17998256.001]
  • [Cites] Cell Mol Neurobiol. 2007 Nov;27(7):831-43 [17703357.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]
  • [Cites] Melanoma Res. 2000 Dec;10(6):507-14 [11198471.001]
  • [Cites] Neurosci Lett. 2001 Feb 16;299(1-2):140-4 [11166957.001]
  • [Cites] J Cell Biol. 1998 Oct 5;143(1):147-57 [9763427.001]
  • [Cites] Front Biosci. 1999 Feb 15;4:D188-99 [9989953.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):387-94 [10433932.001]
  • [Cites] CA Cancer J Clin. 1999 May-Jun;49(3):145-58 [10445014.001]
  • [Cites] J Neurosurg. 1965 Apr;22:368-73 [14318113.001]
  • [Cites] JAMA. 2005 Feb 2;293(5):557-64 [15687310.001]
  • [Cites] Proteomics. 2005 Mar;5(4):1167-77 [15759318.001]
  • [Cites] Tissue Eng. 2005 May-Jun;11(5-6):865-76 [15998226.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):203-12 [11716071.001]
  • [Cites] Cell Mol Neurobiol. 2001 Aug;21(4):421-8 [11775071.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6837-45 [12460896.001]
  • [Cites] Oncogene. 2003 May 1;22(17):2581-91 [12735302.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3407-11 [12776191.001]
  • [Cites] Semin Cell Dev Biol. 2003 Jun;14(3):161-8 [12948350.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 [15459662.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] J Neuropathol Exp Neurol. 1981 May;40(3):201-29 [6260907.001]
  • [Cites] J Neurosci Res. 1981;6(6):741-8 [7334533.001]
  • [Cites] Dev Biol. 1982 Jun;91(2):286-95 [7047260.001]
  • [Cites] Eur J Biochem. 1984 Feb 1;138(3):465-71 [6319134.001]
  • [Cites] Development. 1987 Nov;101(3):565-82 [2458899.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):515-9 [8113864.001]
  • [Cites] Blood. 1994 Jun 1;83(11):3245-54 [7514905.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jul 15;75(2):77-89 [8055485.001]
  • [Cites] Int J Dev Neurosci. 1995 Jun-Jul;13(3-4):213-40 [7572277.001]
  • [Cites] Int J Cancer. 1996 Jul 17;67(2):275-82 [8760599.001]
  • [Cites] Brain Pathol. 1997 Apr;7(2):755-64 [9161727.001]
  • [Cites] Cancer Res. 1993 Aug 1;53(15):3624-31 [8339269.001]
  • (PMID = 18840301.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin
  • [Other-IDs] NLM/ PMC2572634
  •  go-up   go-down


54. D'Angelo A, Capucchio MT, Ferroglio E, Jaggy A: Astrocytoma in a chamois. Schweiz Arch Tierheilkd; 2005 Oct;147(10):453-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Astrocytoma in a chamois.
  • Astrocytomas represent the most common cerebral tumors in humans and in animals, and the fibrillary cytological subtype is the most frequently observed.
  • In this report and for the first time, a thalamic astrocytoma is described in a chamois showing depressed mentation, pleurothotonus and circling to the right side.
  • [MeSH-major] Astrocytoma / veterinary. Brain Neoplasms / veterinary. Goat Diseases / diagnosis. Rupicapra

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259411.001).
  • [ISSN] 0036-7281
  • [Journal-full-title] Schweizer Archiv für Tierheilkunde
  • [ISO-abbreviation] Schweiz. Arch. Tierheilkd.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


55. Gupta M, Djalilvand A, Brat DJ: Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Am J Clin Pathol; 2005 Nov;124(5):755-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
  • Diffuse gliomas are the most common brain tumors and include astrocytomas, oligodendrogliomas, and oligoastrocytomas.
  • Interobserver variability in the diagnosis of diffuse gliomas has been high owing to subjective diagnostic criteria, overlapping morphologic features, and variations in training and practice among pathologists.
  • Combined loss of chromosomes 1p and 19q is a genetic signature of oligodendrogliomas, whereas gains of chromosome 7 in the setting of intact 1p/19q are more typical of astrocytomas.
  • Detection of amplified epidermal growth factor receptor favors the diagnosis of high-grade astrocytomas over anaplastic oligodendroglioma, which is especially relevant for small cell astrocytomas.
  • Strong nuclear staining for p53 often reflects TP53 mutation and is typical of low-grade astrocytomas.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Biomarkers, Tumor. Genes, p53. Genetic Markers. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Loss of Heterozygosity. Mutation. Receptor, Epidermal Growth Factor / genetics


56. Ambroise MM, Khosla C, Ghosh M, Mallikarjuna VS, Annapurneswari S: The role of immunohistochemistry in predicting behavior of astrocytic tumors. Asian Pac J Cancer Prev; 2010;11(4):1079-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 117 cases of astrocytomas graded using the WHO grading system published in 2007 were immunolabeled using p53, EGFR and bcl-2 monoclonal antibodies and analyzed with respect to grade and other relevant parameters.
  • The 117 cases included 16 cases of pilocytic astrocytomas and 25, 15 and 61 cases of diffuse fibrillary astrocytomas WHO grade II, anaplastic astrocytomas WHO grade III and glioblastomas (GBM), respectively.
  • Our results showed that p53 alterations is an early event in astrocytic gliomagenesis, but is not significant in the evolution of pilocytic astrocytomas.
  • [MeSH-major] Astrocytoma / chemistry. Glioblastoma / chemistry. Nervous System Neoplasms / chemistry. Proto-Oncogene Proteins c-bcl-2 / analysis. Receptor, Epidermal Growth Factor / analysis. Tumor Suppressor Protein p53 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21133628.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


57. Momota H, Narita Y, Matsushita Y, Miyakita Y, Shibui S: p53 abnormality and tumor invasion in patients with malignant astrocytoma. Brain Tumor Pathol; 2010 Oct;27(2):95-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 abnormality and tumor invasion in patients with malignant astrocytoma.
  • Malignant astrocytomas are characterized by diffusely infiltrating nature, and the abnormality of p53 is a cytogenetic hallmark of astrocytic tumors.
  • To elucidate the relationship between p53 abnormality and invasiveness of the tumors, we studied mutation and protein expression of p53 in 48 consecutive patients with malignant astrocytoma (14 anaplastic astrocytomas and 34 glioblastoma multiformes).
  • As diffuse and multiple features on imaging modalities represent invasive characteristics of the tumors, p53 abnormalities may affect the invasive and aggressive nature of malignant astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / pathology. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Genes, p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. DNA, Neoplasm / genetics. Female. Glial Fibrillary Acidic Protein / genetics. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Mitotic Index. Mutation / genetics. Mutation / physiology. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Survival Analysis. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Vascular Endothelial Growth Factor A / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046311.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Glial Fibrillary Acidic Protein; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


58. Sievert AJ, Fisher MJ: Pediatric low-grade gliomas. J Child Neurol; 2009 Nov;24(11):1397-408
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cerebellar pilocytic astrocytomas occur most frequently followed by supratentorial diffuse fibrillary astrocytomas.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Blood Cancer. 2009 Jul;52(7):791-5 [19165892.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):449-58 [19016743.001]
  • [Cites] Acta Oncol. 1999;38(8):1051-6 [10665762.001]
  • [Cites] Radiother Oncol. 2000 Mar;54(3):239-45 [10738082.001]
  • [Cites] Pediatr Neurosurg. 2000 Jan;32(1):24-9 [10765135.001]
  • [Cites] J Neurooncol. 1999;45(2):185-90 [10778734.001]
  • [Cites] Brain. 2000 May;123 ( Pt 5):1041-50 [10775548.001]
  • [Cites] Br J Radiol. 2001 Jan;74(877):24-31 [11227773.001]
  • [Cites] Am J Ophthalmol. 2001 Apr;131(4):442-5 [11292406.001]
  • [Cites] Arch Ophthalmol. 2001 Apr;119(4):516-29 [11296017.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Aug-Sep;23(6):349-52 [11563768.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):704-10 [11597812.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Nov-Dec;22(10):1963-9 [11733333.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Nov;131(1):1-12 [11734311.001]
  • [Cites] Pediatr Neurosurg. 2001 Nov;35(5):225-9 [11741114.001]
  • [Cites] Pediatr Neurosurg. 2001 Dec;35(6):311-7 [11786699.001]
  • [Cites] Med Pediatr Oncol. 2002 Mar;38(3):173-7 [11836716.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):325-32 [11872277.001]
  • [Cites] Strahlenther Onkol. 2002 Jan;178(1):10-7 [11977386.001]
  • [Cites] Neurology. 2002 Jul 9;59(1):40-8 [12105305.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4209-16 [12377964.001]
  • [Cites] Pediatr Neurol. 2002 Sep;27(3):165-70 [12393125.001]
  • [Cites] Med Pediatr Oncol. 2003 Jan;40(1):26-34 [12426683.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 May;25(5):372-8 [12759623.001]
  • [Cites] J Pediatr. 1994 Jul;125(1):63-6 [8021787.001]
  • [Cites] Neurology. 1994 Oct;44(10):1798-803 [7936224.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):969-72 [7947106.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):983-98 [7860415.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]
  • [Cites] Acta Neurochir Suppl. 1994;62:67-71 [7717140.001]
  • [Cites] Hum Pathol. 1995 Sep;26(9):979-86 [7672798.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):583-9 [7674005.001]
  • [Cites] Childs Nerv Syst. 1995 Aug;11(8):438-42 [7585678.001]
  • [Cites] Childs Nerv Syst. 1995 Aug;11(8):443-8 [7585679.001]
  • [Cites] Med Pediatr Oncol. 1995 Dec;25(6):431-6 [7565304.001]
  • [Cites] J Neurosurg. 1996 May;84(5):721-5 [8622142.001]
  • [Cites] Neurosurgery. 1996 Jun;38(6):1114-8; discussion 1118-9 [8727140.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] J Neurooncol. 1997 May;32(3):235-41 [9049885.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1438-46 [9083167.001]
  • [Cites] J Neurosurg. 1997 May;86(5):747-54 [9126887.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Aug;97(1):39-53 [9242217.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2792-9 [9256121.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Sep;97(2):125-34 [9283596.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3129-40 [9294476.001]
  • [Cites] Int Rev Neurobiol. 1997;41:411-32 [9378600.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):265-71 [9457808.001]
  • [Cites] Pediatr Neurosurg. 1997 Jul;27(1):12-8 [9486831.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Pediatr Blood Cancer. 2009 Mar;52(3):387-91 [19061216.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):245-50 [18324354.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):245-50 [18386785.001]
  • [Cites] Pediatr Neurosurg. 2008;44(4):324-8 [18504420.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4745-51 [18408760.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • [Cites] J Clin Oncol. 2008 Oct 10;26(29):4765-70 [18779602.001]
  • [Cites] J Child Neurol. 2008 Oct;23(10):1186-94 [18952585.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):153-60 [12816721.001]
  • [Cites] Pediatr Neurol. 2003 Apr;28(4):262-70 [12849878.001]
  • [Cites] J Child Neurol. 2003 Jul;18(7):471-8 [12940652.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):544-53; discussion 554-5 [12943571.001]
  • [Cites] Am J Med Genet A. 2003 Oct 1;122A(2):95-9 [12955759.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):509-20 [14509949.001]
  • [Cites] Br J Neurosurg. 2003 Aug;17(4):327-35 [14579898.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2038-44 [14647135.001]
  • [Cites] Neurosurgery. 2004 Jan;54(1):72-9; discussion 79-80 [14683543.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):706-13 [14966095.001]
  • [Cites] Ophthalmology. 2004 Mar;111(3):568-77 [15019338.001]
  • [Cites] Am J Med Genet A. 2004 Jun 15;127A(3):224-9 [15150770.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jun;146(6):581-8; discussion 588 [15168226.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Oct;26(10):649-55 [15454836.001]
  • [Cites] Cancer. 1975 Jun;35(6):1551-7 [1148989.001]
  • [Cites] Cancer. 1979 Jul;44(1):276-80 [455252.001]
  • [Cites] Lancet. 1981 Nov 7;2(8254):1015-8 [6118478.001]
  • [Cites] J Neurosurg. 1984 Oct;61(4):665-73 [6470776.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Jun;11(6):1067-79 [3997589.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):811-5 [3998829.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):635-42 [3338030.001]
  • [Cites] J Neurosurg. 1989 May;70(5):707-13 [2709111.001]
  • [Cites] J Pediatr. 1989 May;114(5):788-92 [2497236.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):45-52 [2104571.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):815-8 [2323970.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):6-14 [2354409.001]
  • [Cites] BMJ. 1990 Nov 10;301(6760):1077-80 [2249071.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):13-6 [1727109.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1390-6 [1517781.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):215-25 [8420869.001]
  • [Cites] J Neurosurg. 1993 Jun;78(6):859-63 [8487066.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):190-5 [8508405.001]
  • [Cites] J Neurosurg. 1993 Jul;79(1):32-5 [8315466.001]
  • [Cites] Pediatr Neurosurg. 1993 Jul-Aug;19(4):186-95 [8329303.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):856-69 [8334640.001]
  • [Cites] Cancer. 1993 Nov 1;72(9):2746-54 [8402499.001]
  • [Cites] N Engl J Med. 1994 Mar 3;330(9):597-601 [8302341.001]
  • [Cites] Pediatr Neurosurg. 1994;20(1):2-10 [8142279.001]
  • [Cites] J Neurosurg. 1994 Apr;80(4):681-8 [8151347.001]
  • [Cites] Pediatr Neurosurg. 1997 Oct;27(4):203-7 [9577974.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1723-8 [9586884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):979-87 [9719106.001]
  • [Cites] Childs Nerv Syst. 1998 Nov;14(11):636-48 [9840364.001]
  • [Cites] J Neurooncol. 1998 Oct;40(1):39-46 [9874184.001]
  • [Cites] Arch Dis Child. 1998 Oct;79(4):334-8 [9875044.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):265-73 [9950497.001]
  • [Cites] Ann Neurol. 1999 Mar;45(3):393-6 [10072056.001]
  • [Cites] J Neurooncol. 1999 May;42(3):271-88 [10433110.001]
  • [Cites] Haematologica. 1999 Oct;84(10):937-45 [10509043.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1061-8 [10515229.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 2004 Fall;16(4):443-5 [15616170.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):374-9 [15667955.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2755-60 [15805275.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):814-9 [15936565.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jul;45(1):25-31 [15795880.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2636-42 [15861409.001]
  • [Cites] Pediatr Neurol. 2005 Jul;33(1):33-8 [15876519.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5198-204 [16051961.001]
  • [Cites] J Neurosurg. 2005 Mar;102(2 Suppl):172-8 [16156227.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):396-402 [16353203.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • [Cites] Neoplasia. 2006 Feb;8(2):136-42 [16611406.001]
  • [Cites] Pediatr Neurosurg. 2006;42(3):159-64 [16636617.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2570-5 [16735710.001]
  • [Cites] J Neurosurg. 2006 May;104(5 Suppl):314-20 [16848088.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12):1807-16 [16809032.001]
  • [Cites] Childs Nerv Syst. 2006 Sep;22(9):1136-42 [16628460.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4758-63 [16966689.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11172-8 [17145861.001]
  • [Cites] Pediatr Blood Cancer. 2007 Feb;48(2):205-12 [16526054.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):682-9 [17308273.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):161-8 [17347491.001]
  • [Cites] Ann Neurol. 2007 Mar;61(3):189-98 [17387725.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):121-33 [17588166.001]
  • [Cites] Pediatr Blood Cancer. 2007 Nov;49(6):808-11 [17588234.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):73-9 [18177819.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):892-9 [18098210.001]
  • [Cites] Pediatr Dev Pathol. 2008 Mar-Apr;11(2):108-17 [17990938.001]
  • (PMID = 19841428.001).
  • [ISSN] 1708-8283
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA133173-02; United States / NCI NIH HHS / CA / R21 CA133173; United States / NCI NIH HHS / CA / R21 CA133173-02
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 146
  • [Other-IDs] NLM/ NIHMS208342; NLM/ PMC2917804
  •  go-up   go-down


59. Mokhtari K, Paris S, Aguirre-Cruz L, Privat N, Crinière E, Marie Y, Hauw JJ, Kujas M, Rowitch D, Hoang-Xuan K, Delattre JY, Sanson M: Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. Neuropathol Appl Neurobiol; 2005 Feb;31(1):62-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was higher in oligodendrogliomas as compared to astrocytomas and oligoastrocytomas, and in grade III as compared to grade II tumours.
  • In contrast, two main tumour populations, Olig2+/GFAP- and Olig2-/GFAP+, were found in both oligoastrocytomas and astrocytomas.
  • Based on these data from selected samples, two separate entities can be established, corresponding to 'pure oligodendrogliomas' and 'astrocytomas and oligoastrocytomas'.
  • The relevance of this subdivision is further supported by the association with 1p loss and a trend to better survival for pure oligodendrogliomas and with p53 expression and a trend to shorter survival for astrocytomas and oligoastrocytomas.
  • [MeSH-major] Brain Neoplasms / classification. Glial Fibrillary Acidic Protein / metabolism. Glioma / classification. Nerve Tissue Proteins / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15634232.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Glial Fibrillary Acidic Protein; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


60. Lapointe M, Lanthier J, Moumdjian R, Régina A, Desrosiers RR: Expression and activity of l-isoaspartyl methyltransferase decrease in stage progression of human astrocytic tumors. Brain Res Mol Brain Res; 2005 Apr 27;135(1-2):93-103
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More precisely, PIMT levels were significantly lower by 76% in pilocytic astrocytomas (grade I), 46% in astrocytomas (grade II), 69% in anaplastic astrocytomas (grade III), and a marked 80% in glioblastomas (grade IV) as compared to normal brains.
  • RT-PCR analysis showed that levels of type I PIMT mRNA were up-regulated while those of type II PIMT mRNA were down-regulated in glioblastomas.
  • [MeSH-minor] Animals. Blotting, Northern. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry / methods. Male. Methylation. Neoplasm Transplantation / methods. Phosphopyruvate Hydratase / metabolism. RNA, Messenger / metabolism. Rats. Rats, Inbred Lew. Reverse Transcriptase Polymerase Chain Reaction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15857672.001).
  • [ISSN] 0169-328X
  • [Journal-full-title] Brain research. Molecular brain research
  • [ISO-abbreviation] Brain Res. Mol. Brain Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / RNA, Messenger; EC 2.1.1.77 / Protein D-Aspartate-L-Isoaspartate Methyltransferase; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


61. Kamnasaran D, Qian B, Hawkins C, Stanford WL, Guha A: GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model. Proc Natl Acad Sci U S A; 2007 May 8;104(19):8053-8
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model.
  • Malignant astrocytomas are the most common and lethal adult primary brain tumor.
  • Retroviral gene trapping of nontransformed neonatal astrocytes from a glial fibrillary acidic protein (GFAP):(V12)Ha-Ras murine astrocytoma model led to isolation of the transcription factor Gata6.
  • Human malignant astrocytoma cell lines, explant xenografts, and operative specimens demonstrated loss of GATA6 expression.
  • Loss-of-function GATA6 mutations with loss of heterozygosity of the GATA6 locus were found in human malignant astrocytoma specimens but not in lower-grade astrocytomas or normal adult astrocytes.
  • Knockin GATA6 expression in human malignant astrocytoma cells reduced their tumorgenic growth with decreased VEGF expression.
  • Collectively, these data demonstrate that GATA6, isolated from a murine astrocytoma model, is a novel tumor suppressor gene that is a direct target of mutations during malignant progression of murine and human astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. GATA6 Transcription Factor / genetics. Genes, Tumor Suppressor. Glioma / genetics

  • Genetic Alliance. consumer health - Glioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Radiat Res. 2004 Mar;45(1):53-60 [15133290.001]
  • [Cites] Mol Endocrinol. 2004 May;18(5):1144-57 [14988427.001]
  • [Cites] Genes Cells. 2004 Nov;9(11):1083-91 [15507119.001]
  • [Cites] J Neurosurg. 1989 Dec;71(6):826-36 [2585073.001]
  • [Cites] Oncogene. 1992 Jun;7(6):1059-65 [1594239.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Oct;11(2):119-25 [7529548.001]
  • [Cites] Trends Genet. 1995 Oct;11(10):412-5 [7482768.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Jun;123(6):610-4 [9193222.001]
  • [Cites] Oncogene. 1997 Dec 4;15(23):2755-65 [9419966.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13713-8 [9593712.001]
  • [Cites] Acta Neuropathol. 1998 Jun;95(6):617-24 [9650754.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Nature. 2005 Jul 14;436(7048):272-6 [16015333.001]
  • [Cites] Am J Pathol. 2005 Sep;167(3):859-67 [16127163.001]
  • [Cites] Brain Res Dev Brain Res. 2005 Nov 7;160(1):90-5 [16150495.001]
  • [Cites] In Vivo. 2006 Jul-Aug;20(4):511-8 [16900782.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9428-36 [17018597.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4967-77 [12941822.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Oncogene. 1999 Dec 9;18(52):7514-26 [10602510.001]
  • [Cites] J Mol Evol. 2000 Feb;50(2):103-15 [10684344.001]
  • [Cites] Circ Res. 2000 Oct 13;87(8):699-704 [11029406.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6868-74 [11156382.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3826-36 [11325859.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4425-31 [11389071.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):4956-60 [11431323.001]
  • [Cites] Nat Rev Genet. 2001 Oct;2(10):756-68 [11584292.001]
  • [Cites] Genes Cells. 2002 Apr;7(4):435-46 [11952839.001]
  • [Cites] J Neurooncol. 2002 Feb;56(3):197-208 [12061725.001]
  • [Cites] Gene Expr Patterns. 2002 Nov;2(1-2):123-31 [12617850.001]
  • [Cites] Oncogene. 2003 Apr 17;22(15):2361-73 [12700671.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 30;305(2):327-32 [12745078.001]
  • [Cites] Reprod Biol. 2001 Jul;1(1):5-9 [14666170.001]
  • [CommentIn] Proc Natl Acad Sci U S A. 2007 May 8;104(19):7737-8 [17483476.001]
  • (PMID = 17463088.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA6 Transcription Factor; 0 / GATA6 protein, human; 0 / Gata6 protein, mouse
  • [Other-IDs] NLM/ PMC1876570
  •  go-up   go-down


62. Colin C, Virard I, Baeza N, Tchoghandjian A, Fernandez C, Bouvier C, Calisti A, Tong S, Durbec P, Figarella-Branger D: Relevance of combinatorial profiles of intermediate filaments and transcription factors for glioma histogenesis. Neuropathol Appl Neurobiol; 2007 Aug;33(4):431-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to define specific markers for histogenesis of three well-characterized subgroups of human gliomas (pilocytic astrocytomas, glioblastoma multiforme and oligodendrogliomas), we studied the expression of relevant markers that characterize gliomagenesis, by immunohistochemistry and in situ hybridization.
  • They include the intermediate filament proteins glial fibrillary acidic protein (GFAP), vimentin and nestin, the transcription factors Olig2, Nkx2.2 and Sox10, and the proteolipid protein transcripts plp/dm20.
  • Pilocytic astrocytomas strongly express GFAP, vimentin, Olig2, Nkx2.2 and Sox10 but not nestin.
  • [MeSH-minor] Adult. Aged. Basic Helix-Loop-Helix Transcription Factors / genetics. Biomarkers, Tumor. Child. Child, Preschool. DNA-Binding Proteins / genetics. Glial Fibrillary Acidic Protein / biosynthesis. Glial Fibrillary Acidic Protein / genetics. High Mobility Group Proteins / genetics. Homeodomain Proteins / genetics. Humans. Immunohistochemistry. In Situ Hybridization. Intermediate Filament Proteins / biosynthesis. Intermediate Filament Proteins / genetics. Middle Aged. Nerve Tissue Proteins / biosynthesis. Nerve Tissue Proteins / genetics. Nestin. SOXE Transcription Factors. Vimentin / biosynthesis. Vimentin / genetics

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442061.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Glial Fibrillary Acidic Protein; 0 / High Mobility Group Proteins; 0 / Homeodomain Proteins; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Nkx-2.2 homedomain protein; 0 / OLIG2 protein, human; 0 / SOX10 protein, human; 0 / SOXE Transcription Factors; 0 / Transcription Factors; 0 / Vimentin
  •  go-up   go-down


63. Tan KB, Magdalene Koh HK, Tan SY: Double immunofluorescence shows coexpression of Bcl-x with GFAP in a variety of glial lesions. J Neurooncol; 2006 Dec;80(3):235-42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The former included astrocytomas, GBMs, ependymomas, oligodendrogliomas, gangliogliomas, subependymomas and neurocytomas.
  • Expression of Bcl-x closely follows that of GFAP with strong expression in both reactive astrocytes and astrocytomas.
  • [MeSH-major] Astrocytes / metabolism. Brain Neoplasms / metabolism. Glial Fibrillary Acidic Protein / metabolism. Gliosis / metabolism. bcl-X Protein / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16773221.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / bcl-X Protein
  •  go-up   go-down


64. Kim NR, Chung DH, Lee SK, Ha SY: Intramedullary clear cell ependymoma in the thoracic spinal cord: a case with its crush smear and ultrastructural findings. J Korean Med Sci; 2007 Sep;22 Suppl:S149-53
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Astrocytomas outnumber ependymomas in the spinal cord, and the two entities partly share cytologic findings such as long, bipolar glial processes and oval to round nuclei resembling those seen in pilocytic astrocytoma.
  • Cytoplasm had fluffy eosinophilic glial processes, and acellular fibrillary zone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Nov 15;98(10):2232-44 [14601094.001]
  • [Cites] Acta Neuropathol. 1983;62(1-2):141-4 [6659872.001]
  • [Cites] Am J Surg Pathol. 1997 Jul;21(7):820-6 [9236838.001]
  • [Cites] Acta Cytol. 1997 Nov-Dec;41(6):1726-31 [9390132.001]
  • [Cites] Neurol Res. 2003 Jun;25(4):324-8 [12870256.001]
  • [Cites] Neurosurgery. 2000 Dec;47(6):1434-7; discussion 1437-8 [11126915.001]
  • [Cites] Curr Neurol Neurosci Rep. 2003 May;3(3):193-9 [12691623.001]
  • [Cites] Pathol Int. 2003 May;53(5):297-302 [12713564.001]
  • [Cites] Acta Neuropathol. 2000 Feb;99(2):214-8 [10672330.001]
  • (PMID = 17923743.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2694393
  •  go-up   go-down


65. Habek M, Brinar VV, Mubrin Z, Barun B, Zarković K: Bilateral thalamic astrocytoma. J Neurooncol; 2007 Sep;84(2):175-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral thalamic astrocytoma.
  • Brain MRI revealed tumor mass in both thalami and according to WHO classification, the tumor corresponded to diffuse fibrillary astrocytoma grade II.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Thalamus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17522784.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


66. Kotoula V, Cheva A, Barbanis S, Papadimitriou CS, Karkavelas G: hTERT immunopositivity patterns in the normal brain and in astrocytic tumors. Acta Neuropathol; 2006 Jun;111(6):569-78
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prevailing nuclear IPs differed significantly between pilocytic astrocytomas (pattern As) and the rest of histologic types up to glioblastoma (patterns Am and B) (P<0.0001).
  • The nuclear hTERT IPs described here may reflect the functional status of non-neoplastic brain and neoplastic astrocytic cells and support the model of a continuum in the development of glioblastomas from diffuse fibrillary astrocytomas.
  • [MeSH-major] Astrocytes / metabolism. Astrocytoma / metabolism. Brain Chemistry / physiology. Brain Neoplasms / metabolism. Telomerase / genetics. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614861.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fixatives; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 1HG84L3525 / Formaldehyde; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


67. Maramattom BV, Giannini C, Manno EM, Wijdicks EF, Campeau NG: Gliomatosis cerebri angiographically mimicking central nervous system angiitis: case report. Neurosurgery; 2006 Jun;58(6):E1209; discussion E1209
MedlinePlus Health Information. consumer health - Vasculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The biopsy revealed a Grade 2 fibrillary astrocytoma consistent with gliomatosis cerebri.

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16723870.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Ide T, Uchida K, Kikuta F, Suzuki K, Nakayama H: Immunohistochemical characterization of canine neuroepithelial tumors. Vet Pathol; 2010 Jul;47(4):741-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Astrocytomas (n = 4) consisted of cells positive for glial fibrillary acidic protein (GFAP) and nestin and a few cells positive for doublecortin (DCX).
  • Immunoreactive cells for receptor tyrosine kinases (epidermal growth factor receptor and c-erbB2) and their downstream molecules (phospho-extracellular signal-regulated kinase 1/2 and phospho-Akt) were often detected in astrocytomas, especially in medium- and high-grade tumors.
  • In astrocytomas, Bcl-xL-positive cells predominated over Bcl-2-positive cells, but the opposite was observed in oligodendrogliomas.


69. Ikota H, Kinjo S, Yokoo H, Nakazato Y: Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol; 2006 May;111(5):475-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten antibodies [glial fibrillary acidic protein (GFAP), Olig2, vimentin, epithelial membrane antigen (EMA), cytokeratin (AE1/AE3), alpha-internexin, nestin, pinealocytes PP5, aquaporin-4 (AQP4) M13d and AQP4M13e] discriminated between astrocytomas and oligodendroglial tumors.
  • [MeSH-major] Antibodies / immunology. Astrocytoma / immunology. Brain Neoplasms / immunology. Immunohistochemistry / methods. Oligodendroglioma / immunology. Protein Array Analysis / methods
  • [MeSH-minor] Aquaporin 4 / immunology. Aquaporin 4 / metabolism. Basic Helix-Loop-Helix Transcription Factors / immunology. Basic Helix-Loop-Helix Transcription Factors / metabolism. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Cluster Analysis. Diagnosis, Differential. Glial Fibrillary Acidic Protein / immunology. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / immunology. Intermediate Filament Proteins / metabolism. Mucin-1 / immunology. Mucin-1 / metabolism. Nerve Tissue Proteins / immunology. Nerve Tissue Proteins / metabolism. Nestin. Prognosis. Vimentin / immunology. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598485.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Antibodies; 0 / Aquaporin 4; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Mucin-1; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / OLIG2 protein, human; 0 / Vimentin; 0 / alpha-internexin
  •  go-up   go-down


70. Kinjo S, Hirato J, Nakazato Y: Low grade diffuse gliomas: shared cellular composition and morphometric differences. Neuropathology; 2008 Oct;28(5):455-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seventy-eight cases of low grade gliomas were examined including 21 diffuse astrocytomas (DA), 36 oligodendrogliomas (OL), and 21 oligoastrocytomas (OA), based on the WHO classification system.
  • [MeSH-minor] Basic Helix-Loop-Helix Transcription Factors / biosynthesis. Fluorescent Antibody Technique. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Image Interpretation, Computer-Assisted. Immunohistochemistry. Intermediate Filament Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis. Nestin. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18282166.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / OLIG2 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


71. Saad A, Mo J, Miles L, Witte D: Granular cell astrocytoma of the cerebellum: report of the first case. Am J Clin Pathol; 2006 Oct;126(4):602-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell astrocytoma of the cerebellum: report of the first case.
  • Granular cell astrocytomas are an uncommon morphologic variant of infiltrating gliomas characterized by relatively large tumor cells with granular cytoplasm occupying variable proportions of the tumor.
  • These cells coexpressed glial fibrillary acidic protein and CD68.
  • Of the 49 cases of granular cell astrocytomas reported to date, none have involved the cerebellum.
  • The tumor described herein represents the first case of cerebellar granular cell astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Cerebellar Neoplasms / pathology. Granular Cell Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16938663.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Kamnasaran D, Hawkins C, Guha A: Characterization and transformation potential of "Synthetic" astrocytes differentiated from murine embryonic stem cells. Glia; 2008 Mar;56(4):457-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, retroviral transduction of either wt or p53+/- synthetic astrocytes and not the postnatal somatic astrocytes, with relevant oncogenes found in human malignant astrocytomas (MDM2, myr-AKT, V12H-RAS), led to intracranial high-grade undifferentiated gliomas.
  • [MeSH-minor] Animals. Animals, Newborn. Brain / cytology. Brain / embryology. Cell Lineage. Cells, Cultured. Embryo, Mammalian. Fibroblast Growth Factor 2 / pharmacology. Gangliosides / metabolism. Gene Expression Regulation, Developmental / drug effects. Glial Fibrillary Acidic Protein / metabolism. Humans. In Situ Nick-End Labeling. Mice. Mice, Knockout. Oligonucleotide Array Sequence Analysis / methods. Transduction, Genetic / methods. Tumor Suppressor Protein p53 / deficiency

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Copyright) 2008 Wiley-Liss, Inc.
  • (PMID = 18205175.001).
  • [ISSN] 0894-1491
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gangliosides; 0 / Glial Fibrillary Acidic Protein; 0 / Tumor Suppressor Protein p53; 0 / ganglioside A2B5; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


73. Jung CS, Foerch C, Schänzer A, Heck A, Plate KH, Seifert V, Steinmetz H, Raabe A, Sitzer M: Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain; 2007 Dec;130(Pt 12):3336-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A serum marker for malignant cerebral astrocytomas could improve both differential diagnosis and clinical management of brain tumour patients.
  • To evaluate whether the serum concentration of glial fibrillary acidic protein (GFAP) may indicate glioblastoma multiforme (GBM) in patients with single supratentorial space-occupying lesions, we prospectively examined 50 consecutive patients with histologically proven GBM, World Health Organization (WHO) grade IV, 14 patients with anaplastic astrocytoma (WHO grade III), 4 patients with anaplastic oligodendroglioma, 13 patients with diffuse astrocytoma (WHO grade II), 17 patients with a single cerebral metastasis and 50 healthy controls.
  • [MeSH-major] Biomarkers, Tumor / blood. Brain Neoplasms / diagnosis. Glial Fibrillary Acidic Protein / blood. Glioblastoma / diagnosis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998256.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Neoplasm Proteins
  •  go-up   go-down


74. Dutta D, Vanere P, Gupta T, Munshi A, Jalali R: Factors influencing activities of daily living using FIM-FAM scoring system before starting adjuvant treatment in patients with brain tumors: results from a prospective study. J Neurooncol; 2009 Aug;94(1):103-10
MedlinePlus Health Information. consumer health - Stress.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma (GBM) (23.3%), anaplastic astrocytoma (AA) (18.7%), and diffuse fibrillary astrocytoma (18.7%) were the commonest histologic subtypes.
  • A detailed baseline pre-radiotherapy (pre-RT) ADL assessment was done with the FIM-FAM scoring system, which has seven domains with 30 sub-domains (maximum and minimum total scores are 210 and 30).
  • Univariate analysis showed total FIM-FAM scores not significantly different with age (< or =35 years vs. >35 years; P = 0.994), sex (male versus female; P = 0.133), and grade of the tumor (high-grade versus low-grade; P = 0.142) but were significantly higher in patients with a Karnofsky performance score (KPS) of > or =70 as compared with <70 (P = 0.001), neurological performance scale (NPS) of 0 or 1 vs. 2 or 3; P = 0.001), disease type (benign versus malignant; P = 0.001), and site of disease (cerebral versus cerebellar; P = 0.024).
  • There is strong correlation with age, type of tumor, and site of disease with different functional and cognitive domain impairment.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19255726.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


75. Mobley B, Kalani MY, Harsh GR 4th, Edwards MS, Vogel H: Papillary tumor of the spinal cord: report of 2 cases. Am J Surg Pathol; 2009 Aug;33(8):1191-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intramedullary spinal cord tumors constitute a small fraction of central nervous system tumors in the pediatric population; of these, the majority are ependymomas or astrocytomas.
  • We report 2 pediatric spinal cord tumor cases with unique morphologic and immunohistochemical features.
  • Glial fibrillary acidic protein staining was focal in case 1 and completely negative in case 2.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417584.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


76. Chaichana KL, McGirt MJ, Woodworth GF, Datoo G, Tamargo RJ, Weingart J, Olivi A, Brem H, Quinones-Hinojosa A: Persistent outpatient hyperglycemia is independently associated with survival, recurrence and malignant degeneration following surgery for hemispheric low grade gliomas. Neurol Res; 2010 May;32(4):442-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In this study, 182 patients (89 fibrillary astrocytomas, 82 oligodendrogliomas and 11 mixed gliomas) were available for analysis.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19589201.001).
  • [ISSN] 1743-1328
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose
  •  go-up   go-down


77. Loeffler S, Fayard B, Weis J, Weissenberger J: Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer; 2005 Jun 10;115(2):202-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interleukin-6 (IL-6) expression is strongly correlated with the degree of human glioma malignancy and necessary for tumor formation in a mouse model of spontaneous astrocytomas.
  • We demonstrate here that IL-6 drives transcriptional upregulation of VEGF in astrocytes in vivo using glial fibrillary acidic protein (GFAP)-IL-6/VEGF-green fluorescent protein (GFP) double transgenic mice.
  • [MeSH-minor] Animals. COS Cells. Cercopithecus aethiops. Electrophoretic Mobility Shift Assay. GC Rich Sequence / genetics. Glial Fibrillary Acidic Protein / genetics. Glial Fibrillary Acidic Protein / metabolism. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Humans. Immunoprecipitation. Mice. Mice, Transgenic. NIH 3T3 Cells. Neovascularization, Physiologic. STAT3 Transcription Factor. Sequence Deletion. Sp3 Transcription Factor. Transcription Factors / genetics. Transcription Factors / metabolism. Transcriptional Activation

  • Genetic Alliance. consumer health - Glioblastoma.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15688401.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Glial Fibrillary Acidic Protein; 0 / Interleukin-6; 0 / SP3 protein, human; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Sp1 Transcription Factor; 0 / Sp3 protein, mouse; 0 / Stat3 protein, mouse; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Vascular Endothelial Growth Factor A; 147336-22-9 / Green Fluorescent Proteins; 148710-94-5 / Sp3 Transcription Factor
  •  go-up   go-down


78. Larysz D, Blamek S, Larysz P, Pietras K, Mandera M: Posterior fossa brain tissue injury: developmental, neuropsychological, and neurological consequences of brain tumors in children. Acta Neurochir Suppl; 2010;106:271-4
MedlinePlus Health Information. consumer health - Neurologic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathological diagnoses of tumors were as follows: 4 medulloblastomas, 8 pilocytic astrocytomas, 6 fibrillary astrocytomas, 1 anaplastic astrocytoma, 2 oligodendrogliomas, 4 anaplastic ependymomas, 1 choroid plexus papilloma, and 5 arachnoid cysts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19812963.001).
  • [ISSN] 0065-1419
  • [Journal-full-title] Acta neurochirurgica. Supplement
  • [ISO-abbreviation] Acta Neurochir. Suppl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


79. Suárez JC, Viano JC, Zunino S, Herrera EJ, Gomez J, Tramunt B, Marengo I, Hiramatzu E, Miras M, Pena M, Sonzini Astudillo B: Management of child optic pathway gliomas: new therapeutical option. Childs Nerv Syst; 2006 Jul;22(7):679-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosed using computed tomography or/and magnetic resonance imaging, histological studies showed pilocytic astrocytomas in 13 cases and a fibrillary astrocytoma grade II in 1 case.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16389565.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


80. Tanaka Y, Sasaki A, Ishiuchi S, Nakazato Y: Diversity of glial cell components in pilocytic astrocytoma. Neuropathology; 2008 Aug;28(4):399-407
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diversity of glial cell components in pilocytic astrocytoma.
  • To characterize the cellular density and proliferative activity of GFAP-negative cells in pilocytic astrocytoma (PA), surgically excised tissues of PAs (n=37) and diffuse astrocytomas (DAs) (n=11) were examined morphologically and immunohistochemically using antibodies against GFAP, Olig2, Iba1 and Ki-67 (MIB-1).
  • [MeSH-major] Astrocytoma / metabolism. Basic Helix-Loop-Helix Transcription Factors / biosynthesis. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Nerve Tissue Proteins / biosynthesis. Neuroglia / metabolism
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. DNA-Binding Proteins / biosynthesis. Diagnosis, Differential. Female. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Infant, Newborn. Ki-67 Antigen / biosynthesis. Male. Middle Aged

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312545.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / AIF1 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human
  •  go-up   go-down


81. Zhang L, Zhang WP, Hu H, Wang ML, Sheng WW, Yao HT, Ding W, Chen Z, Wei EQ: Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma. Neuropathology; 2006 Apr;26(2):99-106
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma.
  • However, there is still no information available for the expression patterns of 5-LOX in human brain following trauma or with astrocytomas.
  • Furthermore, 5-LOX expression increased and showed a granular pattern in high-grade (grade III/IV) astrocytoma.
  • [MeSH-major] Arachidonate 5-Lipoxygenase / biosynthesis. Astrocytoma / metabolism. Brain / metabolism. Brain Injuries / metabolism. Brain Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Neuroglia / metabolism. Neurons / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708542.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase
  •  go-up   go-down


82. Chumbalkar VC, Subhashini C, Dhople VM, Sundaram CS, Jagannadham MV, Kumar KN, Srinivas PN, Mythili R, Rao MK, Kulkarni MJ, Hegde S, Hegde AS, Samual C, Santosh V, Singh L, Sirdeshmukh R: Differential protein expression in human gliomas and molecular insights. Proteomics; 2005 Mar;5(4):1167-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are the most common of the primary intracranial tumors with astrocytomas constituting about 40%.
  • Using clinically and histologically assessed astrocytomas, we have studied their protein profiles using a two-dimensional gel electrophoresis-mass spectrometry approach and identified differentially expressed proteins which may be useful molecular indicators to understand these tumors.
  • Examination of the protein profiles of 27 astrocytoma samples of different grades revealed 72 distinct, differentially expressed proteins belonging to various functional groups such as cytoskeleton and intermediate filament proteins, heat shock proteins (HSPs), enzymes and regulatory proteins.
  • Based on the consistency of their differential expression, 29 distinct proteins could be short-listed and may have a role in the pathology of astrocytomas.
  • Some were found to be differentially expressed in both Grade III and IV astrocytomas while others were associated with a particular grade.
  • A notable observation was underexpression of Prohibitin, a potential tumor suppressor protein, Rho-GDP dissociation inhibitor, Rho-GDI, a regulator of Rho GTPases and HSPs as well as destabilization of glial fibrillary acidic protein, GFAP, major protein of the glial filaments, in Grade III malignant tumors.
  • [MeSH-major] Astrocytoma / metabolism. Electrophoresis, Gel, Two-Dimensional / methods. Gene Expression Regulation, Neoplastic. Glioma / metabolism. Proteomics / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15759318.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Molecular Chaperones; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


83. Inagawa H, Ishizawa K, Hirose T: Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma. Acta Cytol; 2007 Nov-Dec;51(6):900-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • OBJECTIVE: To evaluate the usefulness of intraoperative cytology for differential diagnoses of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • RESULTS: Astrocytomas were characterized by many fibrillary cytoplasmic processes and large, irregular nuclei.
  • Oligoastrocytomas showed combined cytologic profiles of astrocytomas and oligodendrogliomas.
  • Quantitative studies suggested that nuclei of oligodendroglial tumors were significantly rounder than those of astrocytomas.
  • CONCLUSION; Cytologic evaluation using touch or squash preparations is of great help for intraoperative differential diagnosis of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Cytodiagnosis / methods. Oligodendroglioma / diagnosis


84. Chaichana KL, McGirt MJ, Niranjan A, Olivi A, Burger PC, Quinones-Hinojosa A: Prognostic significance of contrast-enhancing low-grade gliomas in adults and a review of the literature. Neurol Res; 2009 Nov;31(9):931-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: One hundred eighty-nine patients (87 fibrillary astrocytomas, 89 oligodendrogliomas and 13 mixed gliomas) were available for analysis, with 64 (34%) and 125 (66%) contrast-enhancing and non-enhancing tumors, respectively.
  • [MeSH-minor] Adult. Astrocytoma / epidemiology. Astrocytoma / pathology. Craniotomy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local. Oligodendroglioma / epidemiology. Oligodendroglioma / pathology. Predictive Value of Tests. Prognosis. Retrospective Studies. Sensitivity and Specificity. Severity of Illness Index. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215664.001).
  • [ISSN] 1743-1328
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


85. Mei H, Xing Y, Yang A, Wang J, Xu Y, Wang Z, Heiligenhaus A: Astrocytoma of the ciliary body. Ophthalmologica; 2009;223(1):72-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Astrocytoma of the ciliary body.
  • PURPOSE: To report the occurrence of an astrocytoma of the ciliary body.
  • Histopathology revealed a fibrillary astrocytoma.
  • Staining for glial fibrillary acidic protein yielded positive results and neuron-specific enolase yielded negative results.
  • CONCLUSIONS: We describe an astrocytoma of the ciliary body in a patient, which is an extremely rare ocular tumor.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / surgery. Ciliary Body. Uveal Neoplasms / diagnosis. Uveal Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry / methods. Microscopy, Acoustic. Phosphopyruvate Hydratase / analysis. Staining and Labeling. Ultrasonography, Doppler, Color

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 19033704.001).
  • [ISSN] 1423-0267
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


86. El-Jawahri A, Patel D, Zhang M, Mladkova N, Chakravarti A: Biomarkers of clinical responsiveness in brain tumor patients : progress and potential. Mol Diagn Ther; 2008;12(4):199-208
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anaplastic astrocytoma and glioblastoma multiforme represent malignant astrocytomas, which are the most common type of malignant gliomas.
  • Other promising biomarkers in glioma research include glial fibrillary acidic protein, galectins, Kir potassium channel proteins, angiogenesis, and apoptosis pathway markers.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652516.001).
  • [ISSN] 1177-1062
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA108633
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 71
  •  go-up   go-down


87. Rodriguez FJ, Scheithauer BW, Burger PC, Jenkins S, Giannini C: Anaplasia in pilocytic astrocytoma predicts aggressive behavior. Am J Surg Pathol; 2010 Feb;34(2):147-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplasia in pilocytic astrocytoma predicts aggressive behavior.
  • The clinical significance of anaplastic features, a rare event in pilocytic astrocytoma (PA), is not fully established.
  • The tumors either had a PA precursor, coexistent (n = 14) (41%) or documented by previous biopsy (n = 10) (29%), or exhibited typical pilocytic features in an otherwise anaplastic astrocytoma (n = 10) (29%).
  • Histologically, the anaplastic component was classified as pilocytic like (41%), small cell (32%), epithelioid (15%), or fibrillary (12%).
  • Overall and progression-free survivals were shorter in the setting of prior radiation for a PA precursor (P = 0.007, 0.028), increasing mitotic activity (P = 0.03, 0.02), and presence of necrosis (P = 0.02, 0.02), after adjusting for age and site.
  • The biologic behavior of PAs with high-mitotic rates and those with necrosis paralleled that of St Anne-Mayo grades 2 and 3 diffuse astrocytomas, respectively.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061938.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


88. Kuhlmann T, Gutenberg A, Schulten HJ, Paulus W, Rohde V, Bruck W: Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas? Am J Surg Pathol; 2008 Oct;32(10):1444-53
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a minority of cases, the differentiation between astrocytomas and oligodendrogliomas based on morphologic characteristics alone can be difficult; though it is important, as patients with oligodendrogliomas follow a more favorable clinical course.
  • Here we report on the immunohistochemical expression pattern of the oligodendrocytic marker Nogo-A in 113 central nervous system tumors including 28 oligodendrogliomas [15, World Health Organization (WHO) grade II; 13, grade WHO III], 50 astrocytomas [10, grade WHO II; 11, grade WHO III; 29 glioblastoma multiforme (GBM)], 11 ependymomas WHO grade II, 7 central neurocytomas, 2 dysembryoplastic neuroepithelial tumors (DNTs), 5 clear cell meningiomas, and 10 metastases to the brain.
  • The oligodendrocytic marker Nogo-A was found to be strongly expressed in 71% of oligodendrogliomas, but in 0% of ependymomas WHO grade II, astrocytomas WHO grade II or III, DNTs, central neurocytomas, or clear cell meningiomas.
  • In GBM, a subgroup of tumors (24%) showed strong expression of Nogo-A coincidently with Ki67 positivity but glial fibrillary acidic protein-negativity.
  • Our findings indicate that Nogo-A is strongly expressed in the majority of oligodendrogliomas and might be a helpful marker to distinguish oligodendrogliomas from astrocytomas WHO grades II and III as well as ependymomas.
  • [MeSH-minor] Astrocytoma / chemistry. Diagnosis, Differential. Ependymoma / chemistry. Gene Expression Regulation, Neoplastic. Glioblastoma / chemistry. Humans. Immunohistochemistry. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18685489.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Myelin Proteins; 0 / Nogo protein
  •  go-up   go-down


89. Tchoghandjian A, Fernandez C, Colin C, El Ayachi I, Voutsinos-Porche B, Fina F, Scavarda D, Piercecchi-Marti MD, Intagliata D, Ouafik L, Fraslon-Vanhulle C, Figarella-Branger D: Pilocytic astrocytoma of the optic pathway: a tumour deriving from radial glia cells with a specific gene signature. Brain; 2009 Jun;132(Pt 6):1523-35
Genetic Alliance. consumer health - Pilocytic astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilocytic astrocytoma of the optic pathway: a tumour deriving from radial glia cells with a specific gene signature.
  • Pilocytic astrocytomas are WHO grade I gliomas that occur predominantly in childhood.
  • Understanding the molecular basis responsible for the aggressive behaviour of hypothalamo-chiasmatic pilocytic astrocytomas is a prerequisite to setting up new molecular targeted therapies.
  • We used the microarray technique to compare the transcriptional profiles of five hypothalamo-chiasmatic and six cerebellar pilocytic astrocytomas.
  • Results demonstrate that cerebellar and hypothalamo-chiasmatic pilocytic astrocytomas are two genetically distinct and topography-dependent entities.
  • Numerous genes upregulated in hypothalamo-chiasmatic pilocytic astrocytomas also increased in the developing chiasm, suggesting that developmental genes mirror the cell of origin whereas migrative, adhesive and proliferative genes reflect infiltrative properties of these tumours.
  • Of particular interest, NOTCH2, a gene expressed in radial glia and involved in gliomagenesis, was upregulated in hypothalamo-chiasmatic pilocytic astrocytomas.
  • In order to find progenitor cells that could give rise to hypothalamo-chiasmatic pilocytic astrocytomas, we performed a morphological study of the hypothalamo-chiasmatic region and identified, in the floor of the third ventricle, a unique population of vimentin- and glial fibrillary acidic protein-positive cells highly suggestive of radial glia cells.
  • Therefore, pilocytic astrocytomas of the hypothalamo-chiasmatic region should be considered as a distinct entity which probably originates from a unique population of cells with radial glia phenotype.
  • [MeSH-major] Astrocytoma / diagnosis. Optic Nerve Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336457.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Vimentin
  •  go-up   go-down


90. Shamji MF, Benoit BG, Perry A, Jansen GH: Giant cell ependymoma of the thoracic spine: pathology case report. Neurosurgery; 2009 Mar;64(3):E566-7; discussion E567
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unusual histological subtypes can make intraoperative diagnosis spurious, possibly altering the surgical approach from gross total resection for ependymomas to debulking for high-grade astrocytomas.
  • Intraoperative pathology suggested a high-grade glioblastoma, but final section showed sporadic giant cells with marked pleomorphism, uniform immunofluorescence staining with both glial fibrillary acidic protein and cluster of differentiation 99, and high MIB-1 index.

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19240583.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Kurian KM, Summers DM, Statham PF, Smith C, Bell JE, Ironside JW: Third ventricular chordoid glioma: clinicopathological study of two cases with evidence for a poor clinical outcome despite low grade histological features. Neuropathol Appl Neurobiol; 2005 Aug;31(4):354-61
Genetic Alliance. consumer health - Glioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main differentials for histological diagnosis include chordoid meningiomas, pilocytic astrocytomas and ependymomas.
  • An immunohistochemical panel including antibodies to glial fibrillary acidic protein, CD 34, epithelial membrane antigen, pan cytokeratin, S100 and vimentin can be used to distinguish between these possibilities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008819.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


92. Benesch M, Eder HG, Sovinz P, Raith J, Lackner H, Moser A, Urban C: Residual or recurrent cerebellar low-grade glioma in children after tumor resection: is re-treatment needed? A single center experience from 1983 to 2003. Pediatr Neurosurg; 2006;42(3):159-64
Genetic Alliance. consumer health - Glioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 289 patients with CNS tumors referred between 1983 and 2003, 28 (9.7%) (15 male, 13 female; median age at diagnosis: 71 months) had cerebellar LGG (pilocytic astrocytoma grade I: n = 21; fibrillary astrocytoma grade II: n = 5; mixed hamartoma/pilocytic astrocytoma: n = 1; radiographic diagnosis: n = 1).
  • [MeSH-major] Astrocytoma / surgery. Cerebellar Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel
  • (PMID = 16636617.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down






Advertisement